diff --git a/.github/prehooks/commit-msg b/.github/prehooks/commit-msg index 6e18ce448..503f0e877 100755 --- a/.github/prehooks/commit-msg +++ b/.github/prehooks/commit-msg @@ -14,7 +14,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/.github/prehooks/pre-commit b/.github/prehooks/pre-commit index 08a12a134..ec70ed2e2 100755 --- a/.github/prehooks/pre-commit +++ b/.github/prehooks/pre-commit @@ -14,7 +14,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/.github/workflows/check-current-testthat-dev-versions.yaml b/.github/workflows/check-current-testthat-dev-versions.yaml index ea4bc6f04..44594e069 100644 --- a/.github/workflows/check-current-testthat-dev-versions.yaml +++ b/.github/workflows/check-current-testthat-dev-versions.yaml @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/.github/workflows/check-current-testthat.yaml b/.github/workflows/check-current-testthat.yaml index 0a318cc8d..187c7abab 100644 --- a/.github/workflows/check-current-testthat.yaml +++ b/.github/workflows/check-current-testthat.yaml @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/.github/workflows/check-old-tinytest.yaml b/.github/workflows/check-old-tinytest.yaml index 6eab5ec78..e6f4cc7f7 100644 --- a/.github/workflows/check-old-tinytest.yaml +++ b/.github/workflows/check-old-tinytest.yaml @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/.github/workflows/codecovr.yaml b/.github/workflows/codecovr.yaml index 5c9004f67..ae94b20fd 100644 --- a/.github/workflows/codecovr.yaml +++ b/.github/workflows/codecovr.yaml @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/.github/workflows/publish-to-pypi.yml b/.github/workflows/publish-to-pypi.yml index b792dde65..1042e5ec2 100644 --- a/.github/workflows/publish-to-pypi.yml +++ b/.github/workflows/publish-to-pypi.yml @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/.github/workflows/renew-gpt-training-data.yml b/.github/workflows/renew-gpt-training-data.yml index 391f3bfa7..c7580c228 100644 --- a/.github/workflows/renew-gpt-training-data.yml +++ b/.github/workflows/renew-gpt-training-data.yml @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/.github/workflows/todo-tracker.yml b/.github/workflows/todo-tracker.yml index 921539737..3c7d750e0 100644 --- a/.github/workflows/todo-tracker.yml +++ b/.github/workflows/todo-tracker.yml @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/.github/workflows/website.yaml b/.github/workflows/website.yaml index 175e6bb35..e5306ce9f 100644 --- a/.github/workflows/website.yaml +++ b/.github/workflows/website.yaml @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/DESCRIPTION b/DESCRIPTION index b8365893a..e7033e4b8 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -1,6 +1,6 @@ Package: AMR -Version: 3.0.1.9086 -Date: 2026-08-13 +Version: 3.0.1.9087 +Date: 2026-08-20 Title: Antimicrobial Resistance Data Analysis Description: Functions to simplify and standardise antimicrobial resistance (AMR) data analysis and to work with microbial and antimicrobial properties by diff --git a/NEWS.md b/NEWS.md index 10796428b..36671c023 100644 --- a/NEWS.md +++ b/NEWS.md @@ -1,9 +1,28 @@ -# AMR 3.0.1.9086 +# AMR 3.0.1.9087 -Planned as v3.1.0, end of June 2026. +Planned as v3.1.0, end of September 2026. ### Breaking Changes * The former *kingdoms* Bacteria and Archaea are now each divided into four kingdoms with new top-level *domains* 'Bacteria' and 'Archaea' (Göker and Oren, 2024, DOI: 10.1099/ijsem.0.006242). Following this, a new `domain` column in the `microorganisms` data set was added, and more importantly, `mo_kingdom()` now returns the formal kingdom (e.g. `"Pseudomonadati"` instead of `"Bacteria"`). Use `mo_domain()` for the old behaviour. For non-prokaryotic kingdoms (Fungi, Protozoa, etc.), `kingdom` and `domain` are identical. + + | `mo_kingdom()` < 3.1.0 | `mo_kingdom()` now | `mo_domain()` (unchanged) | + |------------------------|---------------------|---------------------------| + | Bacteria | Bacillati | Bacteria | + | | Fusobacteriati | Bacteria | + | | Pseudomonadati | Bacteria | + | | Thermotogati | Bacteria | + | | | | + | Archaea | Methanobacteriati | Archaea | + | | Nanobdellati | Archaea | + | | Promethearchaeati | Archaea | + | | Thermoproteati | Archaea | + | | | | + | Fungi | Fungi | Fungi | + | | | | + | Protozoa | Protozoa | Protozoa | + + Thus, `mo_domain()` was previously an alias of `mo_kingdom()`; it is now a distinct function returning the domain. Output of `mo_domain()` is therefore unchanged, while `mo_kingdom()` now returns the formal, new kingdom. + * Faster parallel computing via the `future` package for `as.sir()` and `wisca()`: a non-sequential plan (e.g. `future::plan(future::multisession)`) must be active before using `parallel = TRUE`. ### New diff --git a/R/aa_amr-package.R b/R/aa_amr-package.R index 1958354aa..658935369 100755 --- a/R/aa_amr-package.R +++ b/R/aa_amr-package.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/aa_globals.R b/R/aa_globals.R index e035468f4..ac69e49e8 100755 --- a/R/aa_globals.R +++ b/R/aa_globals.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/aa_helper_functions.R b/R/aa_helper_functions.R index f8bb6d198..e2fa96d98 100755 --- a/R/aa_helper_functions.R +++ b/R/aa_helper_functions.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/aa_helper_pm_functions.R b/R/aa_helper_pm_functions.R index 93a9a2236..87675ebba 100755 --- a/R/aa_helper_pm_functions.R +++ b/R/aa_helper_pm_functions.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/aa_options.R b/R/aa_options.R index 482a7a181..5c567c592 100755 --- a/R/aa_options.R +++ b/R/aa_options.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/ab.R b/R/ab.R index 896b56256..b9fb9df03 100755 --- a/R/ab.R +++ b/R/ab.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/ab_from_text.R b/R/ab_from_text.R index c9705f1ae..c68e71d34 100755 --- a/R/ab_from_text.R +++ b/R/ab_from_text.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/ab_property.R b/R/ab_property.R index 84adad5e2..8adef951b 100755 --- a/R/ab_property.R +++ b/R/ab_property.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/age.R b/R/age.R index 1f6a5b6b0..624fc7f5d 100755 --- a/R/age.R +++ b/R/age.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/amr_course.R b/R/amr_course.R index e188e3afb..5a5709c8a 100755 --- a/R/amr_course.R +++ b/R/amr_course.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/amr_selectors.R b/R/amr_selectors.R index fee6c4cdd..ba65eb3cd 100755 --- a/R/amr_selectors.R +++ b/R/amr_selectors.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/antibiogram.R b/R/antibiogram.R index 9a2b200b0..473374ff9 100755 --- a/R/antibiogram.R +++ b/R/antibiogram.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/atc_online.R b/R/atc_online.R index dcc588000..11e0f2ba6 100755 --- a/R/atc_online.R +++ b/R/atc_online.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/av.R b/R/av.R index 72898e9cf..eaf5c6fb7 100755 --- a/R/av.R +++ b/R/av.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/av_from_text.R b/R/av_from_text.R index d07dc81bb..fed167ac6 100755 --- a/R/av_from_text.R +++ b/R/av_from_text.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/av_property.R b/R/av_property.R index d2001596b..a6b565c9d 100755 --- a/R/av_property.R +++ b/R/av_property.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/availability.R b/R/availability.R index f14aefb8c..32a7d4429 100755 --- a/R/availability.R +++ b/R/availability.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/bug_drug_combinations.R b/R/bug_drug_combinations.R index a2d78971a..09e5c0755 100755 --- a/R/bug_drug_combinations.R +++ b/R/bug_drug_combinations.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/count.R b/R/count.R index daa0ad9a7..0b78535cc 100755 --- a/R/count.R +++ b/R/count.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/custom_antimicrobials.R b/R/custom_antimicrobials.R index 509768422..068ccdb11 100755 --- a/R/custom_antimicrobials.R +++ b/R/custom_antimicrobials.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/custom_interpretive_rules.R b/R/custom_interpretive_rules.R index be2a61c78..11f5e3f79 100755 --- a/R/custom_interpretive_rules.R +++ b/R/custom_interpretive_rules.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/custom_mdro_guideline.R b/R/custom_mdro_guideline.R index bfa181644..e7a933f35 100755 --- a/R/custom_mdro_guideline.R +++ b/R/custom_mdro_guideline.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/custom_microorganisms.R b/R/custom_microorganisms.R index 5f9e008bc..799fd9ff7 100755 --- a/R/custom_microorganisms.R +++ b/R/custom_microorganisms.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/data.R b/R/data.R index 279c61556..b3697d79b 100755 --- a/R/data.R +++ b/R/data.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # @@ -312,7 +312,14 @@ #' The default is `"human"`, which can also be set with the package option [`AMR_breakpoint_type`][AMR-options]. Use [`as.sir(..., breakpoint_type = ...)`][as.sir()] to interpret raw data using a specific breakpoint type, e.g. `as.sir(..., breakpoint_type = "ECOFF")` to use ECOFFs. #' #' ### Imported From WHONET -#' Clinical breakpoints in this package were validated through and imported from [WHONET](https://whonet.org), a free desktop Windows application developed and supported by the WHO Collaborating Centre for Surveillance of Antimicrobial Resistance. More can be read on [their website](https://whonet.org). The developers of WHONET and this `AMR` package have been in contact about sharing their work. We highly appreciate their great development on the WHONET software. +#' Some breakpoints in this package were validated through and imported from [WHONET](https://whonet.org), a free desktop Windows application developed and supported by the WHO Collaborating Centre for Surveillance of Antimicrobial Resistance. More can be read on [their website](https://whonet.org). The developers of WHONET and this `AMR` package have been in contact about sharing their work. We highly appreciate their great development on the WHONET software. +#' +#' From WHONET, imported were: +#' +#' * All CLSI breakpoints, including ECOFF +#' * EUCAST breakpoints between `r min(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, guideline %like% "EUCAST" & type == "human")$guideline)))` and 2018 +#' +#' EUCAST breakpoints from 2019 onwards, were retrieved directly from . #' #' Our import and reproduction script can be found here: . #' diff --git a/R/disk.R b/R/disk.R index 45b4a2021..c1b686445 100755 --- a/R/disk.R +++ b/R/disk.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/export_biosample.R b/R/export_biosample.R index 32056f4da..38d959604 100755 --- a/R/export_biosample.R +++ b/R/export_biosample.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/first_isolate.R b/R/first_isolate.R index df4cfdf0b..271379058 100755 --- a/R/first_isolate.R +++ b/R/first_isolate.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/g.test.R b/R/g.test.R index c07886ded..42ec9c223 100755 --- a/R/g.test.R +++ b/R/g.test.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/get_episode.R b/R/get_episode.R index bc9dc58eb..441372b48 100755 --- a/R/get_episode.R +++ b/R/get_episode.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/ggplot_pca.R b/R/ggplot_pca.R index 2651d1155..226d53c7f 100755 --- a/R/ggplot_pca.R +++ b/R/ggplot_pca.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/ggplot_sir.R b/R/ggplot_sir.R index b275bb8b3..a1efa9b5c 100755 --- a/R/ggplot_sir.R +++ b/R/ggplot_sir.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/guess_ab_col.R b/R/guess_ab_col.R index b51698c12..83366f298 100755 --- a/R/guess_ab_col.R +++ b/R/guess_ab_col.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/interpretive_rules.R b/R/interpretive_rules.R index 642406355..0ae0cca86 100755 --- a/R/interpretive_rules.R +++ b/R/interpretive_rules.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/italicise_taxonomy.R b/R/italicise_taxonomy.R index c47ac82ff..5f625a622 100755 --- a/R/italicise_taxonomy.R +++ b/R/italicise_taxonomy.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/join_microorganisms.R b/R/join_microorganisms.R index e282b9933..373f1b476 100755 --- a/R/join_microorganisms.R +++ b/R/join_microorganisms.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/key_antimicrobials.R b/R/key_antimicrobials.R index e99112b49..128dafa1d 100755 --- a/R/key_antimicrobials.R +++ b/R/key_antimicrobials.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/kurtosis.R b/R/kurtosis.R index 167320b47..c64259686 100755 --- a/R/kurtosis.R +++ b/R/kurtosis.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/like.R b/R/like.R index 62f52300c..0d412005b 100755 --- a/R/like.R +++ b/R/like.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/mdro.R b/R/mdro.R index 10d1698d8..cdb3448ef 100755 --- a/R/mdro.R +++ b/R/mdro.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/mean_amr_distance.R b/R/mean_amr_distance.R index 905e99d9d..bcb236312 100755 --- a/R/mean_amr_distance.R +++ b/R/mean_amr_distance.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/mic.R b/R/mic.R index 8b3e74299..f431d3392 100755 --- a/R/mic.R +++ b/R/mic.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/mo.R b/R/mo.R index 5a5c81217..f98e17c7a 100755 --- a/R/mo.R +++ b/R/mo.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/mo_matching_score.R b/R/mo_matching_score.R index 2e0064bcd..2384c3912 100755 --- a/R/mo_matching_score.R +++ b/R/mo_matching_score.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/mo_property.R b/R/mo_property.R index 525f2ebaf..7fc44f906 100755 --- a/R/mo_property.R +++ b/R/mo_property.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # @@ -44,19 +44,19 @@ #' #' [mo_ref()] returns the abbreviated authority of the nomenclatural act that created the queried name combination. When `keep_synonyms = FALSE` (default), this is the authority of the currently accepted name. When `keep_synonyms = TRUE`, this is the authority under which the queried (possibly outdated) name was published. Emendations (changes to the species description without a name change) are not reflected; only the combination or original description authority is returned. #' -#' The short name ([mo_shortname()]) returns the first character of the genus and the full species, such as `"E. coli"`, for species and subspecies. Exceptions are abbreviations of staphylococci (such as *"CoNS"*, Coagulase-Negative Staphylococci) and beta-haemolytic streptococci (such as *"GBS"*, Group B Streptococci). Please bear in mind that e.g. *E. coli* could mean *Escherichia coli* (kingdom of Bacteria) as well as *Entamoeba coli* (kingdom of Protozoa). Returning to the full name will be done using [as.mo()] internally, giving priority to bacteria and human pathogens, i.e. `"E. coli"` will always be considered *Escherichia coli*. As a result, `mo_fullname(mo_shortname("Entamoeba coli"))` returns `"Escherichia coli"`. +#' The short name ([mo_shortname()]) returns the first character of the genus and the full species, such as `"E. coli"`, for species and subspecies. Exceptions are abbreviations of staphylococci (such as *"CoNS"*, Coagulase-Negative Staphylococci) and beta-haemolytic streptococci (such as *"GBS"*, Group B Streptococci). Please bear in mind that e.g. *E. coli* could mean *Escherichia coli* (domain of Bacteria) as well as *Entamoeba coli* (domain of Protozoa). Returning to the full name will be done using [as.mo()] internally, giving priority to bacteria and human pathogens, i.e. `"E. coli"` will always be considered *Escherichia coli*. As a result, `mo_fullname(mo_shortname("Entamoeba coli"))` returns `"Escherichia coli"`. #' #' Following the formal introduction of the new kingdom rank into prokaryotic nomenclature in 2024 (\doi{10.1099/ijsem.0.006242}), [mo_kingdom()] and [mo_domain()] return different results for bacteria and archaea: [mo_kingdom()] returns the new formal kingdom (e.g. "Pseudomonadati", "Bacillati"), while [mo_domain()] returns the new domain (e.g. "Bacteria", "Archaea"). For non-prokaryotic organisms, both functions return identical results. #' #' Determination of human pathogenicity ([mo_pathogenicity()]) is strongly based on Bartlett *et al.* (2022, \doi{10.1099/mic.0.001269}). This function returns a [factor] with the levels *Pathogenic*, *Potentially pathogenic*, *Non-pathogenic*, and *Unknown*. #' -#' Determination of the Gram stain ([mo_gramstain()] is based on the taxonomic kingdom and phylum. Originally, Cavalier-Smith defined the so-called subkingdoms Negibacteria and Posibacteria (2002, [PMID 11837318](https://pubmed.ncbi.nlm.nih.gov/11837318/)), and only considered these phyla as Posibacteria: Actinobacteria, Chloroflexi, Firmicutes, and Tenericutes. These phyla were later renamed to Actinomycetota, Chloroflexota, Bacillota, and Mycoplasmatota (2021, [PMID 34694987](https://pubmed.ncbi.nlm.nih.gov/34694987/)). Bacteria in these phyla are considered Gram-positive in this `AMR` package, except for members of the class Negativicutes (within phylum Bacillota) which are Gram-negative. All other bacteria are considered Gram-negative. Species outside the kingdom of Bacteria will return a value `NA`. Functions [mo_is_gram_negative()] and [mo_is_gram_positive()] always return `TRUE` or `FALSE` (or `NA` when the input is `NA` or the MO code is `UNKNOWN`), thus always return `FALSE` for species outside the taxonomic kingdom of Bacteria. +#' Determination of the Gram stain ([mo_gramstain()] is based on the taxonomic domain and phylum. Originally, Cavalier-Smith defined the so-called subkingdoms Negibacteria and Posibacteria (2002, [PMID 11837318](https://pubmed.ncbi.nlm.nih.gov/11837318/)), and only considered these phyla as Posibacteria: Actinobacteria, Chloroflexi, Firmicutes, and Tenericutes. These phyla were later renamed to Actinomycetota, Chloroflexota, Bacillota, and Mycoplasmatota (2021, [PMID 34694987](https://pubmed.ncbi.nlm.nih.gov/34694987/)). Bacteria in these phyla are considered Gram-positive in this `AMR` package, except for members of the class Negativicutes (within phylum Bacillota) which are Gram-negative. All other bacteria are considered Gram-negative. Species outside the kingdom of Bacteria will return a value `NA`. Functions [mo_is_gram_negative()] and [mo_is_gram_positive()] always return `TRUE` or `FALSE` (or `NA` when the input is `NA` or the MO code is `UNKNOWN`), thus always return `FALSE` for species outside the taxonomic kingdom of Bacteria. #' -#' Determination of yeasts ([mo_is_yeast()]) is based on the taxonomic kingdom and class. *Budding yeasts* are yeasts that reproduce asexually through a process called budding, where a new cell develops from a small protrusion on the parent cell. Taxonomically, these are members of the phylum Ascomycota, class Saccharomycetes (also called Hemiascomycetes) or Pichiomycetes. *True yeasts* quite specifically refers to yeasts in the underlying order Saccharomycetales (such as *Saccharomyces cerevisiae*). Thus, for all microorganisms that are member of the taxonomic class Saccharomycetes or Pichiomycetes, the function will return `TRUE`. It returns `FALSE` otherwise (or `NA` when the input is `NA` or the MO code is `UNKNOWN`). +#' Determination of yeasts ([mo_is_yeast()]) is based on the taxonomic domain and class. *Budding yeasts* are yeasts that reproduce asexually through a process called budding, where a new cell develops from a small protrusion on the parent cell. Taxonomically, these are members of the phylum Ascomycota, class Saccharomycetes (also called Hemiascomycetes) or Pichiomycetes. *True yeasts* quite specifically refers to yeasts in the underlying order Saccharomycetales (such as *Saccharomyces cerevisiae*). Thus, for all microorganisms that are member of the taxonomic class Saccharomycetes or Pichiomycetes, the function will return `TRUE`. It returns `FALSE` otherwise (or `NA` when the input is `NA` or the MO code is `UNKNOWN`). #' #' Determination of intrinsic resistance ([mo_is_intrinsic_resistant()]) is based on the [intrinsic_resistant] data set, which is based on `r format_eucast_version_nr(names(EUCAST_VERSION_EXPECTED_PHENOTYPES[1]))`. The [mo_is_intrinsic_resistant()] function can be vectorised over both argument `x` (input for microorganisms) and `ab` (input for antimicrobials). #' -#' Determination of both bacterial oxygen tolerance ([mo_oxygen_tolerance()]) and morphology ([mo_morphology()]) are based on BacDive, see *Source*. The function [mo_is_anaerobic()] only returns `TRUE` if the oxygen tolerance is `"anaerobe"`, indicating an obligate anaerobic species or genus. It always returns `FALSE` for species outside the taxonomic kingdom of Bacteria. +#' Determination of both bacterial oxygen tolerance ([mo_oxygen_tolerance()]) and morphology ([mo_morphology()]) are based on BacDive, see *Source*. The function [mo_is_anaerobic()] only returns `TRUE` if the oxygen tolerance is `"anaerobe"`, indicating an obligate anaerobic species or genus. It always returns `FALSE` for species outside the taxonomic domain of Bacteria. #' #' The function [mo_url()] will return the direct URL to the online database entry, which also shows the scientific reference of the concerned species. [This MycoBank URL](`r TAXONOMY_VERSION$MycoBank$url`) is used for fungi wherever available , [this LPSN URL](`r TAXONOMY_VERSION$MycoBank$url`) for bacteria wherever available, and [this GBIF link](`r TAXONOMY_VERSION$GBIF$url`) otherwise. #' diff --git a/R/mo_source.R b/R/mo_source.R index 6c58ad600..cf678670a 100755 --- a/R/mo_source.R +++ b/R/mo_source.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/pca.R b/R/pca.R index c7e2fc820..c9bc383ee 100755 --- a/R/pca.R +++ b/R/pca.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/plotting.R b/R/plotting.R index bfecb3d4f..97f0bd800 100755 --- a/R/plotting.R +++ b/R/plotting.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/proportion.R b/R/proportion.R index 03ecd6abf..9303d33a2 100755 --- a/R/proportion.R +++ b/R/proportion.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/random.R b/R/random.R index d5dd7b8b8..7d2a7bffd 100755 --- a/R/random.R +++ b/R/random.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/resistance_predict.R b/R/resistance_predict.R index eb0928ebe..2a1028bc2 100755 --- a/R/resistance_predict.R +++ b/R/resistance_predict.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/sir.R b/R/sir.R index 138086b87..0f84ae677 100755 --- a/R/sir.R +++ b/R/sir.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/sir_calc.R b/R/sir_calc.R index c836d9599..8c3eec53a 100755 --- a/R/sir_calc.R +++ b/R/sir_calc.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/sir_df.R b/R/sir_df.R index 3d2e6d1e2..1d12c7c15 100755 --- a/R/sir_df.R +++ b/R/sir_df.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/skewness.R b/R/skewness.R index 9c6955bb5..3376dae7c 100755 --- a/R/skewness.R +++ b/R/skewness.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/top_n_microorganisms.R b/R/top_n_microorganisms.R index 9d237d644..71de54749 100755 --- a/R/top_n_microorganisms.R +++ b/R/top_n_microorganisms.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/translate.R b/R/translate.R index 6690aa144..821d44c5c 100755 --- a/R/translate.R +++ b/R/translate.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/vctrs.R b/R/vctrs.R index 904f1e0db..5b83e8fc2 100755 --- a/R/vctrs.R +++ b/R/vctrs.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/whocc.R b/R/whocc.R index 444d25ad1..46c92bf1c 100755 --- a/R/whocc.R +++ b/R/whocc.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/zz_deprecated.R b/R/zz_deprecated.R index 66f4076db..088302c0f 100755 --- a/R/zz_deprecated.R +++ b/R/zz_deprecated.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/R/zzz.R b/R/zzz.R index 16f33fabb..1e81a70e3 100755 --- a/R/zzz.R +++ b/R/zzz.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/_pkgdown.yml b/_pkgdown.yml index a47b12f86..d5116649e 100644 --- a/_pkgdown.yml +++ b/_pkgdown.yml @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # @@ -56,7 +56,7 @@ footer: left: [devtext] right: [logo] components: - devtext: 'AMR (for R). Free and open-source, licenced under the GNU GPL 2.0. Developed at the University of Groningen and University Medical Center Groningen in The Netherlands, in collaboration with many colleagues from around the world.' + devtext: 'AMR (for R). Free and open-source, licenced under the GNU GPL 2.0. Developed at the University of Groningen and University Medical Center Groningen in the Netherlands, in collaboration with many colleagues from around the world.' logo: '' home: diff --git a/codecov.yml b/codecov.yml index d02dc544e..c250aa794 100644 --- a/codecov.yml +++ b/codecov.yml @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_generate_python_wrapper.sh b/data-raw/_generate_python_wrapper.sh index 077b5c134..a1f8e6b9e 100644 --- a/data-raw/_generate_python_wrapper.sh +++ b/data-raw/_generate_python_wrapper.sh @@ -14,7 +14,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_language_update.R b/data-raw/_language_update.R index 5e1b4d0af..04836ef67 100644 --- a/data-raw/_language_update.R +++ b/data-raw/_language_update.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_pre_commit_checks.R b/data-raw/_pre_commit_checks.R index 13578f2cf..daf935538 100644 --- a/data-raw/_pre_commit_checks.R +++ b/data-raw/_pre_commit_checks.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_reproduction_scripts/reproduction_of_antimicrobials.R b/data-raw/_reproduction_scripts/reproduction_of_antimicrobials.R index 57899fbfe..b044102af 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_antimicrobials.R +++ b/data-raw/_reproduction_scripts/reproduction_of_antimicrobials.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_reproduction_scripts/reproduction_of_antivirals.R b/data-raw/_reproduction_scripts/reproduction_of_antivirals.R index 2a9a2e7bf..12790ae44 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_antivirals.R +++ b/data-raw/_reproduction_scripts/reproduction_of_antivirals.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R b/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R index 2f9e3e708..1d0aaf131 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R +++ b/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R b/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R index f347e6c3f..fb040b221 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R +++ b/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # @@ -39,8 +39,9 @@ # Uses tidyxl to parse rich text cells, separating base values from # superscript footnote references that EUCAST uses for notes. # -# Output mimics the AMR::clinical_breakpoints structure with added columns: -# version, is_screening, note +# Output mimics the AMR::clinical_breakpoints structure with an added +# `version` column (guideline already covers the year; version keeps the +# exact x.y string), plus `sheet` and `note`. library(tidyxl) @@ -51,10 +52,19 @@ devtools::load_all() # ============================================================================== # 1. Rich text parser # ============================================================================== +# Struck-through runs (tidyxl: character_formatted$strike == TRUE) are always +# disregarded before splitting base text from superscript note references, +# since EUCAST uses strike-through to mark removed/superseded text within a +# cell (most commonly within Notes blocks) that must not end up in the parsed +# output. split_rich_text <- function(fmt_list) { map_dfr(fmt_list, function(fmt) { if (is.null(fmt) || nrow(fmt) == 0) return(tibble(base_text = NA_character_, note_super = NA_character_)) + is_struck <- !is.na(fmt$strike) & fmt$strike + fmt <- fmt[!is_struck, , drop = FALSE] + if (nrow(fmt) == 0) + return(tibble(base_text = NA_character_, note_super = NA_character_)) is_super <- !is.na(fmt$vertAlign) & fmt$vertAlign == "superscript" tibble( base_text = paste0(fmt$character[!is_super], collapse = ""), @@ -63,6 +73,131 @@ split_rich_text <- function(fmt_list) { }) } +# ============================================================================== +# 1b. Agent-name / organism-restriction splitter +# ============================================================================== +# On some sheets, the agent-name cell (column A) additionally restricts the +# row's breakpoints to a subset of the sheet's overall organism scope, e.g. +# Staphylococcus sheet: "Amikacin, Coagulase-negative staphylococci" (the +# same antibiotic gets different breakpoints for S. aureus vs coagulase- +# negative staphylococci), or Enterobacterales sheet: "Cefuroxime iv, +# E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +# P. mirabilis". Parsing this from prose would be fragile (parenthetical +# route/indication qualifiers like "(uncomplicated UTI only)" are +# syntactically indistinguishable from organism qualifiers in free text). +# +# EUCAST instead encodes this distinction through formatting: the +# antibiotic name (including any parenthetical route/indication qualifier) +# is always bold, matching the sheet's hyperlink-styled agent-name +# convention, while an appended organism restriction is always set in a +# run with bold explicitly turned off. Splitting on this formatting +# boundary is far more robust than any text-pattern approach, and matches +# how EUCAST's own spreadsheet authors distinguish the two. +# +# The split point is the earliest run after which every remaining +# non-superscript run is non-bold (this correctly keeps a bold parenthetical +# that appears mid-cell, e.g. "Meropenem(indications other than +# meningitis), Pseudomonas other than P. aeruginosa" is not split at the +# first non-bold run (an empty separator) but at the true boundary before +# "Pseudomonas"). Superscript note-reference runs (which are always bold, +# by EUCAST convention, regardless of position) are excluded before this +# check, since they are handled separately by split_rich_text() and are +# not part of either the agent name or the organism restriction. +# +# If a multi-run cell's bold pattern never settles into an all-non-bold +# tail (i.e. no valid split point exists), the format is unexpected for +# this convention and the function errors rather than guessing, per design: +# in practice every EUCAST agent-name cell observed follows this +# convention, so a failure here should surface a genuine anomaly in a +# future version of the table rather than be silently absorbed. This is +# why `valid_rows` restricts the check to the actual data rows of the +# sheet's organism table(s) (computed by the caller once the table +# boundaries are known): column A elsewhere on a sheet can contain prose +# (section introductions, cross-references to another sheet's table) that +# was never an antibiotic name and has no reason to follow this +# convention, so it must not be able to trip the error at all. +split_agent_organism <- function(cells, formats, sheet_name, valid_rows) { + col_a <- cells |> filter(col == 1, !is_blank, row %in% valid_rows) + if (nrow(col_a) == 0) { + return(tibble(row = integer(0), ab_text = character(0), mo_override = character(0))) + } + base_bold <- formats$local$font$bold[col_a$local_format_id] + + out <- vector("list", nrow(col_a)) + for (i in seq_len(nrow(col_a))) { + fmt <- col_a$character_formatted[[i]] + row_i <- col_a$row[i] + + if (is.null(fmt) || nrow(fmt) == 0) { + # Plain (non-rich-text) cell: nothing to split, whole text is the agent name + out[[i]] <- tibble(row = row_i, ab_text = col_a$character[i], mo_override = NA_character_) + next + } + + # Drop struck-through and superscript runs first, exactly as split_rich_text() does + is_struck <- !is.na(fmt$strike) & fmt$strike + fmt <- fmt[!is_struck, , drop = FALSE] + is_super <- !is.na(fmt$vertAlign) & fmt$vertAlign == "superscript" + fmt <- fmt[!is_super, , drop = FALSE] + + if (nrow(fmt) <= 1) { + txt <- if (nrow(fmt) == 1) fmt$character[1] else col_a$character[i] + out[[i]] <- tibble(row = row_i, ab_text = txt, mo_override = NA_character_) + next + } + + bold_resolved <- ifelse(is.na(fmt$bold), base_bold[i], fmt$bold) + n <- length(bold_resolved) + # Find the earliest k (k < n) such that runs (k+1):n are all non-bold + split_at <- NA_integer_ + for (k in seq_len(n - 1)) { + if (all(!bold_resolved[(k + 1):n])) { + split_at <- k + break + } + } + + if (is.na(split_at)) { + # Either the whole cell is bold (no restriction present -> fine, keep + # as a single agent name) or the bold pattern never settles into an + # all-non-bold tail, which is the genuinely unexpected case. + if (all(bold_resolved) || !any(bold_resolved)) { + out[[i]] <- tibble(row = row_i, + ab_text = paste0(fmt$character, collapse = ""), + mo_override = NA_character_) + next + } + stop( + "split_agent_organism(): unexpected bold pattern in column A, sheet '", + sheet_name, "', row ", row_i, ": bold never settles to a non-bold tail. ", + "Text: '", paste0(fmt$character, collapse = ""), "'. ", + "This breaks the assumption that antibiotic names are bold and any ", + "trailing organism restriction is not; inspect this cell manually." + ) + } + + ab_text <- paste0(fmt$character[seq_len(split_at)], collapse = "") + mo_override <- paste0(fmt$character[(split_at + 1):n], collapse = "") + out[[i]] <- tibble(row = row_i, ab_text = ab_text, mo_override = mo_override) + } + + bind_rows(out) |> + mutate( + ab_text = trimws(gsub("[\r\n]+", " ", ab_text)), + ab_text = gsub(",\\s*$", "", ab_text), + mo_override = trimws(gsub("[\r\n]+", " ", mo_override)), + # The comma separating the agent name from the restriction is not + # always formatted consistently: it is usually part of the bold + # agent-name run (so ab_text's trailing-comma strip above handles + # it), but is occasionally fused into the start of the non-bold + # restriction run instead, e.g. Staphylococcus sheet "Daptomycin, + # other staphylococci" -- leaving a leading ", " on mo_override that + # would otherwise reach as.mo() and fail to resolve. + mo_override = sub("^,\\s*", "", mo_override), + mo_override = na_if(mo_override, "") + ) +} + # ============================================================================== # 2. Notes block parser # ============================================================================== @@ -225,11 +360,6 @@ parse_bp <- function(txt) { t } -is_screening_fn <- function(txt) { - if (is.na(txt)) return(FALSE) - grepl("^\\(.+\\)$", trimws(txt)) -} - format_disk_dose <- function(dose) { if (is.na(dose) || dose == "") return(NA_character_) d <- trimws(dose) @@ -242,10 +372,17 @@ format_disk_dose <- function(dose) { # 5. Detect version and guideline from workbook # ============================================================================== detect_version <- function(cells) { - # Version string is typically in col 5+ of row 1 (or sometimes col 9) + # The version string sits in row 1, in whichever column follows the + # organism name in col A. Its column position is NOT fixed: it depends on + # how many data columns the sheet has (e.g. col I for sheets with MIC and + # disk columns, but col C or E for MIC-only sheets such as N. gonorrhoeae + # or H. pylori, which have fewer columns). Detecting it by requiring + # col >= 5 therefore misses those narrower sheets. Instead, take every + # non-blank cell in row 1 other than col A (the organism name), which is + # robust regardless of sheet width. # e.g. "EUCAST Clinical Breakpoint Tables v. 13.1, valid from 2023-06-29" version_cells <- cells |> - filter(row == 1, !is_blank, col >= 5) |> + filter(row == 1, !is_blank, col > 1) |> mutate(text = coalesce(character, "")) version_text <- paste(version_cells$text, collapse = " ") @@ -254,10 +391,35 @@ detect_version <- function(cells) { version <- gsub("v\\.?\\s*", "", version) if (length(version) == 0) version <- NA_character_ - major <- suppressWarnings(as.integer(sub("\\..*", "", version))) - guideline <- if (!is.na(major)) paste0("EUCAST ", major + 2010) else NA_character_ + # The guideline year is read directly from the "valid from YYYY-MM-DD" + # date in the version string, not derived from the version number: the + # two are not reliably related. EUCAST's bacterial clinical breakpoint + # tables happen to have incremented their major version roughly once a + # year since inception, which coincidentally makes "major version + 2010" + # look right for those files, but the antifungal (AFST) table keeps its + # own, independent version sequence -- v12.1 of the AFST table is dated + # "valid from 2026-04-10", i.e. EUCAST 2026, not the "2022" that + # "12 + 2010" would wrongly produce. Every version string observed + # carries exactly one 4-digit year in its "valid from" date, so a direct + # regex on that is both simpler and correct for both table families. + year <- regmatches(version_text, regexpr("(?<=valid from )\\d{4}", version_text, perl = TRUE)) + if (length(year) == 0) { + # Fall back to any 4-digit year anywhere in the string, in case a + # future version string omits the "valid from" wording but still + # states a year somewhere. + year <- regmatches(version_text, regexpr("\\d{4}", version_text)) + } + guideline <- if (length(year) == 1) paste0("EUCAST ", year) else NA_character_ - list(version = version, guideline = guideline) + # A human-readable description of the source file/table, for ref_tbl, + # e.g. "Clinical Breakpoint Tables v. 16.1" or "Antifungal Clinical + # Breakpoint Table v. 12.1" -- everything in the version string between + # the leading "EUCAST " and the trailing ", valid from ..." date. + file_desc <- sub("^EUCAST\\s+", "", version_text) + file_desc <- trimws(sub(",?\\s*valid from.*$", "", file_desc, ignore.case = TRUE)) + if (!nzchar(file_desc)) file_desc <- NA_character_ + + list(version = version, guideline = guideline, file_desc = file_desc) } # ============================================================================== @@ -269,6 +431,8 @@ parse_sheet <- function(xlsx_path, sheet_name) { # --- Detect version --- ver <- detect_version(cells) + formats <- xlsx_formats(xlsx_path) + # --- Parse rich text for cols A:I --- target <- cells |> filter(col >= 1, col <= 9, !is_blank) rich <- split_rich_text(target$character_formatted) @@ -301,13 +465,49 @@ parse_sheet <- function(xlsx_path, sheet_name) { # Sub-header rows: one row below each header (contains "S " pattern) sub_header_rows <- header_rows + 1 + # --- Detect the notes column --- + # On sheets that report both MIC and disk breakpoints, columns are laid out + # as: A agent | B-D MIC (S/R/ATU) | E-H disk (dose/S/R/ATU) | I notes. + # On sheets that report MIC only (no disk diffusion method exists, e.g. + # N. gonorrhoeae, N. meningitidis, H. pylori, M. tuberculosis), columns D-H + # are absent and the layout collapses to: A agent | B-D MIC (S/R/ATU) | + # E notes. The notes column therefore shifts from I to E. Rather than + # hard-coding either position, detect it per sheet from the header row + # itself: it is the right-most populated column on the header row (the + # cell whose text starts with "Notes"). + header_row_cols <- parsed |> + filter(row %in% header_rows, col > 3, grepl("^Notes", base_text)) |> + pull(col) + + notes_col <- if (length(header_row_cols) > 0) { + # Normally consistent across header rows within a sheet; take the modal + # (most frequent) value defensively in case of stray formatting cells. + as.integer(names(sort(table(header_row_cols), decreasing = TRUE))[1]) + } else { + 9L # fallback to the conventional position if no "Notes" label is found + } + + # Data columns run up to (but excluding) the notes column; disk columns + # are only present when notes_col > 5 (i.e. the sheet is wider than a + # MIC-only layout of A:E). + has_disk_columns <- notes_col > 5 + # --- Detect sheet type: single-organism vs multi-organism --- - # Multi-organism: col A at header rows contains "Antimicrobial agent" + # Multi-organism: col A at header rows contains "Antimicrobial agent". + # This label alone is not sufficient, though: some genuinely single- + # organism sheets (e.g. M. tuberculosis) also happen to use "Antimicrobial + # agent" at their (single) header row, rather than an antibiotic class + # name. The reliable distinguishing signal is the number of header rows: + # a sheet with only one MIC breakpoint header is single-organism + # regardless of that header's col-A label, since true multi-organism + # sheets (Anaerobic bacteria, Topical agents) repeat the header once per + # organism. header_col_a <- parsed |> filter(row %in% header_rows, col == 1) |> pull(base_text) - is_multi_organism <- all(grepl("Antimicrobial agent", header_col_a, fixed = TRUE)) + is_multi_organism <- length(header_rows) > 1 && + all(grepl("Antimicrobial agent", header_col_a, fixed = TRUE)) # --- Detect organisms and their table ranges --- max_data_row <- max(parsed$row) @@ -349,21 +549,21 @@ parse_sheet <- function(xlsx_path, sheet_name) { last_data <- header_rows[i + 1] - 1 # Walk back to find actual last data row while (last_data >= first_data) { - has_data <- nrow(parsed |> filter(row == last_data, col %in% 2:8)) > 0 + has_data <- nrow(parsed |> filter(row == last_data, col %in% setdiff(2:8, notes_col))) > 0 if (has_data) break last_data <- last_data - 1 } } else { last_data <- max_data_row while (last_data >= first_data) { - has_data <- nrow(parsed |> filter(row == last_data, col %in% 2:8)) > 0 + has_data <- nrow(parsed |> filter(row == last_data, col %in% setdiff(2:8, notes_col))) > 0 if (has_data) break last_data <- last_data - 1 } } - # Notes cell: col 9, in the data range (usually at first_data, merged) - note_cell <- parsed |> filter(col == 9, row >= first_data, row <= last_data) |> + # Notes cell: notes_col, in the data range (usually at first_data, merged) + note_cell <- parsed |> filter(col == notes_col, row >= first_data, row <= last_data) |> slice_min(row, n = 1) note_text <- if (nrow(note_cell) > 0) note_cell$base_text[1] else NA_character_ notes_parsed <- parse_notes_block(note_text) @@ -378,7 +578,7 @@ parse_sheet <- function(xlsx_path, sheet_name) { # Clean: remove trailing * or whitespace organism <- gsub("[*]+$", "", trimws(organism)) - # Notes: col 9, within each class section + # Notes: notes_col, within each class section # For single-organism sheets, there is one notes block per class. # Notes cell is at the header row or first data row of each class. tables <- list() @@ -390,22 +590,22 @@ parse_sheet <- function(xlsx_path, sheet_name) { if (i < length(header_rows)) { last_data <- header_rows[i + 1] - 1 while (last_data >= first_data) { - has_data <- nrow(parsed |> filter(row == last_data, col %in% 2:8)) > 0 + has_data <- nrow(parsed |> filter(row == last_data, col %in% setdiff(2:8, notes_col))) > 0 if (has_data) break last_data <- last_data - 1 } } else { last_data <- max_data_row while (last_data >= first_data) { - has_data <- nrow(parsed |> filter(row == last_data, col %in% 2:8)) > 0 + has_data <- nrow(parsed |> filter(row == last_data, col %in% setdiff(2:8, notes_col))) > 0 if (has_data) break last_data <- last_data - 1 } } - # Notes: look in col 9 from header row through end of section + # Notes: look in notes_col from header row through end of section note_cells <- parsed |> - filter(col == 9, row >= hr, row <= last_data, + filter(col == notes_col, row >= hr, row <= last_data, !grepl("^Notes", base_text)) note_text <- if (nrow(note_cells) > 0) { paste(note_cells$base_text, collapse = "\n") @@ -420,6 +620,17 @@ parse_sheet <- function(xlsx_path, sheet_name) { } # --- Extract breakpoint rows --- + # Split agent name from any organism restriction in column A (see + # split_agent_organism() for the formatting-based rationale). This is + # scoped to the actual data rows of each organism table, computed just + # above, rather than run across the whole column: prose cells elsewhere + # in column A (section intros, cross-references to other sheets) are not + # antibiotic names and are not expected to follow the bold-name / + # non-bold-restriction convention, so they must not be able to trip the + # "unexpected format" error at all. + data_rows <- unique(unlist(map(tables, function(tbl) tbl$first_data:tbl$last_data))) + agent_org_split <- split_agent_organism(cells, formats, sheet_name, valid_rows = data_rows) + results <- vector("list", 500) idx <- 0L @@ -430,25 +641,60 @@ parse_sheet <- function(xlsx_path, sheet_name) { for (r in tbl$first_data:tbl$last_data) { agent <- get_cell(parsed, r, 1) if (is.na(agent$base)) next - # Skip category headers (rows that have col A text but no data in B:H) - has_any_data <- any(!is.na(c( - get_cell(parsed, r, 2)$base, - get_cell(parsed, r, 3)$base, - get_cell(parsed, r, 5)$base, - get_cell(parsed, r, 6)$base, - get_cell(parsed, r, 7)$base - ))) + # Skip category headers (rows that have col A text but no data). + # Columns 5:7 only hold disk data when the sheet actually has disk + # columns; on MIC-only sheets col 5 is the notes column and must not + # be treated as a data indicator. + data_cols <- if (has_disk_columns) c(2, 3, 5, 6, 7) else c(2, 3) + has_any_data <- any(!is.na(vapply(data_cols, function(cc) get_cell(parsed, r, cc)$base, + character(1)))) if (!has_any_data) next + # Agent name and any organism restriction encoded in its formatting + # (see split_agent_organism()). Falls back to the raw cell text and + # the table-level organism when this row has no split entry (e.g. + # plain-text cells with no rich formatting at all). + split_row <- agent_org_split[agent_org_split$row == r, ] + agent_text <- if (nrow(split_row) > 0) split_row$ab_text[1] else agent$base + row_mo <- if (nrow(split_row) > 0 && !is.na(split_row$mo_override[1])) { + split_row$mo_override[1] + } else { + org + } + mic_s <- get_cell(parsed, r, 2) mic_r <- get_cell(parsed, r, 3) mic_atu <- get_cell(parsed, r, 4) - disk_dose_cell <- get_cell(parsed, r, 5) - disk_s <- get_cell(parsed, r, 6) - disk_r <- get_cell(parsed, r, 7) - disk_atu <- get_cell(parsed, r, 8) + # Disk columns (E:H) only exist on sheets that report disk diffusion + # breakpoints. On MIC-only sheets, col E is the notes column instead + # of the disk dose, so disk cells must not be read from it there. + if (has_disk_columns) { + disk_dose_cell <- get_cell(parsed, r, 5) + disk_s <- get_cell(parsed, r, 6) + disk_r <- get_cell(parsed, r, 7) + disk_atu <- get_cell(parsed, r, 8) + } else { + disk_dose_cell <- list(base = NA_character_, super = NA_character_) + disk_s <- list(base = NA_character_, super = NA_character_) + disk_r <- list(base = NA_character_, super = NA_character_) + disk_atu <- list(base = NA_character_, super = NA_character_) + } - note_text <- resolve_notes(nl, mic_s$super, disk_s$super) + # Notes must apply only to the method they were referenced from: MIC + # superscripts resolve to the MIC row's note, disk superscripts to the + # DISK row's note. Resolving both against the union of MIC and disk + # references (as before) duplicated every note into both rows. + # A superscript on the agent name itself (col A) is method-agnostic + # and must be folded into both sides, e.g. L. monocytogenes + # "Trimethoprim-sulfamethoxazole (all indications)1". + combine_super <- function(...) { + parts <- c(...) + parts <- parts[!is.na(parts) & parts != ""] + if (length(parts) == 0) return(NA_character_) + paste(parts, collapse = ",") + } + mic_note <- resolve_notes(nl, combine_super(mic_s$super, agent$super), NA) + disk_note <- resolve_notes(nl, NA, combine_super(disk_s$super, agent$super)) # MIC row s_val <- parse_bp(mic_s$base) @@ -458,21 +704,18 @@ parse_sheet <- function(xlsx_path, sheet_name) { results[[idx]] <- tibble( guideline = ver$guideline, version = ver$version, + file_desc = ver$file_desc, type = "human", host = "human", method = "MIC", site = NA_character_, - mo = org, + mo = row_mo, rank_index = NA_integer_, - ab = agent$base, - ref_tbl = org, + ab = agent_text, disk_dose = NA_character_, breakpoint_S = s_val, breakpoint_R = r_val, - uti = FALSE, - is_SDD = FALSE, - is_screening = is_screening_fn(mic_s$base), - note = note_text + note = mic_note ) } @@ -484,21 +727,18 @@ parse_sheet <- function(xlsx_path, sheet_name) { results[[idx]] <- tibble( guideline = ver$guideline, version = ver$version, + file_desc = ver$file_desc, type = "human", host = "human", method = "DISK", site = NA_character_, - mo = org, + mo = row_mo, rank_index = NA_integer_, - ab = agent$base, - ref_tbl = org, + ab = agent_text, disk_dose = format_disk_dose(disk_dose_cell$base), breakpoint_S = s_val, breakpoint_R = r_val, - uti = FALSE, - is_SDD = FALSE, - is_screening = is_screening_fn(disk_s$base), - note = note_text + note = disk_note ) } } @@ -598,13 +838,12 @@ parse_topical_sheet <- function(xlsx_path) { if (!is.na(mic_val)) { idx <- idx + 1L results[[idx]] <- tibble( - guideline = ver$guideline, version = ver$version, + guideline = ver$guideline, version = ver$version, file_desc = ver$file_desc, type = "human", host = "human", method = "MIC", site = "Topical", mo = od$organism, rank_index = NA_integer_, - ab = ab_name, ref_tbl = "Topical agents", + ab = ab_name, disk_dose = NA_character_, breakpoint_S = mic_val, breakpoint_R = mic_val, - uti = FALSE, is_SDD = FALSE, is_screening = TRUE, note = mic_note ) } @@ -619,13 +858,12 @@ parse_topical_sheet <- function(xlsx_path) { if (!is.na(disk_val)) { idx <- idx + 1L results[[idx]] <- tibble( - guideline = ver$guideline, version = ver$version, + guideline = ver$guideline, version = ver$version, file_desc = ver$file_desc, type = "human", host = "human", method = "DISK", site = "Topical", mo = od$organism, rank_index = NA_integer_, - ab = ab_name, ref_tbl = "Topical agents", + ab = ab_name, disk_dose = ab_dose, breakpoint_S = disk_val, breakpoint_R = disk_val, - uti = FALSE, is_SDD = FALSE, is_screening = TRUE, note = disk_note ) } @@ -637,7 +875,169 @@ parse_topical_sheet <- function(xlsx_path) { } # ============================================================================== -# 8. Parse all data sheets +# 8. Parse antifungal sheets with a transposed species-in-columns layout +# (EUCAST AFST tables: "Yeast", "Aspergillus") +# ============================================================================== +# Layout differs from the bacterial sheets in two ways: +# - Species run across column-blocks rather than down rows. Each block is +# 2 columns wide (S/R) or 3 (S/R/ATU), detected dynamically from the +# sub-header row rather than assumed fixed-width, since Aspergillus mixes +# 2- and 3-column species blocks on the same sheet. +# - Notes sit in a block below the table, one full note per row (starting +# "1. ", "2. " etc.) rather than a single merged cell to the right of the +# table; these are concatenated and handed to the same parse_notes_block() +# used elsewhere. +# Antifungal breakpoints on these sheets are MIC-only; there is no disk +# diffusion method, so only method = "MIC" rows are produced. +parse_yeast_sheet <- function(xlsx_path, sheet_name) { + cells <- xlsx_cells(xlsx_path, sheets = sheet_name) + + ver <- detect_version(cells) + + target <- cells |> filter(!is_blank) + rich <- split_rich_text(target$character_formatted) + parsed <- target |> + bind_cols(rich) |> + mutate( + base_text = case_when( + !is.na(base_text) & base_text != "" ~ trimws(base_text), + !is.na(character) ~ trimws(character), + !is.na(numeric) ~ as.character(numeric), + TRUE ~ NA_character_ + ), + note_super = if_else(is.na(note_super) | note_super == "", + NA_character_, note_super) + ) |> + select(row, col, base_text, note_super) + + # --- Locate the "Antifungal agent" header row --- + hdr_row <- parsed |> + filter(col == 1, grepl("^Antifungal agent$", base_text)) |> + pull(row) + if (length(hdr_row) == 0) { + message(" No 'Antifungal agent' header found in sheet '", sheet_name, "', skipping") + return(NULL) + } + hdr_row <- hdr_row[1] + species_row <- hdr_row + 1L + sub_row <- hdr_row + 2L + first_data_row <- hdr_row + 3L + + # --- Detect species column-blocks from the sub-header row --- + # Each block starts at a cell reading "S <=" (S \u2264) and runs through the + # next "R >" and, where present, an immediately following "ATU" column, + # stopping before the next "S <=" or the end of populated columns. + sub_cells <- parsed |> filter(row == sub_row) |> arrange(col) + s_cols <- sub_cells |> filter(grepl("^S\\b", base_text)) |> pull(col) + + if (length(s_cols) == 0) { + message(" No species S/R columns found in sheet '", sheet_name, "', skipping") + return(NULL) + } + + species_blocks <- list() + for (i in seq_along(s_cols)) { + s_col <- s_cols[i] + r_col <- s_col + 1L + # ATU present if the cell two columns after S reads "ATU" (i.e. this + # block is 3 columns wide rather than 2) + atu_cell <- get_cell(parsed, sub_row, s_col + 2L) + has_atu <- !is.na(atu_cell$base) && grepl("^ATU\\b", atu_cell$base) + + sp_cell <- get_cell(parsed, species_row, s_col) + species <- if (!is.na(sp_cell$base)) gsub("\r?\n", " ", sp_cell$base) else NA_character_ + if (is.na(species)) next + # Expand an abbreviated genus initial (e.g. "A. terreus") to the + # sheet's own genus ("Aspergillus terreus") before this reaches + # as.mo(): a bare genus initial is ambiguous across unrelated genera + # with no context to disambiguate, and this is not merely theoretical + # here -- as.mo("A. terreus") alone resolves to Acinetobacter + # terrestris, not Aspergillus terreus, since Acinetobacter has a + # matching species epithet and nothing here signals which genus was + # meant. The sheet name is used as this genus reference; it consists + # of only the bare genus for both AFST sheets this parser handles + # ("Yeast" is actually genus-mixed and not abbreviated in practice, so + # this only fires for "Aspergillus"). + sheet_genus <- sub("^.*?([A-Z][a-z]+).*$", "\\1", trimws(sheet_name)) + if (grepl("^[A-Z]\\.\\s", species) && substr(species, 1, 1) == substr(sheet_genus, 1, 1)) { + species <- sub("^[A-Z]\\.", sheet_genus, species) + } + + species_blocks[[length(species_blocks) + 1]] <- list( + species = species, s_col = s_col, r_col = r_col, + atu_col = if (has_atu) s_col + 2L else NA_integer_ + ) + } + + # --- Locate the end of the data block (row before the "Notes" label) --- + notes_label_row <- parsed |> + filter(col == 1, grepl("^Notes$", base_text), row > first_data_row) |> + pull(row) + last_data_row <- if (length(notes_label_row) > 0) { + min(notes_label_row) - 1L + } else { + max(parsed$row) + } + + # --- Notes block: one note per row below the "Notes" label, col A --- + notes_text <- if (length(notes_label_row) > 0) { + note_cells <- parsed |> + filter(col == 1, row > min(notes_label_row)) |> + arrange(row) + paste(note_cells$base_text, collapse = "\n") + } else { + "" + } + notes_lookup <- parse_notes_block(notes_text) + + # --- Extract breakpoint rows: one per (agent, species) combination --- + results <- vector("list", 1000) + idx <- 0L + + for (r in first_data_row:last_data_row) { + agent_cell <- get_cell(parsed, r, 1) + if (is.na(agent_cell$base)) next + agent_name <- gsub("\r?\n", " ", agent_cell$base) + agent_super <- agent_cell$super + + for (sb in species_blocks) { + s_cell <- get_cell(parsed, r, sb$s_col) + r_cell <- get_cell(parsed, r, sb$r_col) + + s_val <- parse_bp(s_cell$base) + r_val <- parse_bp(r_cell$base) + if (is.na(s_val) && is.na(r_val)) next + + all_supers <- c(s_cell$super, r_cell$super, agent_super) + all_supers <- all_supers[!is.na(all_supers) & all_supers != ""] + note_text <- resolve_notes(notes_lookup, paste(all_supers, collapse = ","), NA) + + idx <- idx + 1L + results[[idx]] <- tibble( + guideline = ver$guideline, + version = ver$version, + file_desc = ver$file_desc, + type = "human", + host = "human", + method = "MIC", + site = NA_character_, + mo = sb$species, + rank_index = NA_integer_, + ab = agent_name, + disk_dose = NA_character_, + breakpoint_S = s_val, + breakpoint_R = r_val, + note = note_text + ) + } + } + + if (idx == 0) return(NULL) + bind_rows(results[seq_len(idx)]) +} + +# ============================================================================== +# 9. Parse all data sheets # ============================================================================== parse_workbook <- function(xlsx_path, skip_sheets = c("Content", "Changes", "Notes", @@ -647,14 +1047,27 @@ parse_workbook <- function(xlsx_path, "PKPD breakpoints", "PK PD breakpoints")) { all_sheets <- xlsx_sheet_names(xlsx_path) - data_sheets <- setdiff(all_sheets, skip_sheets) + + # Some workbooks (e.g. the antifungal AFST tables) number-prefix their + # sheet names, e.g. "1. Notes", "7. Dosages", "6. Aspergillus ", and are + # not always consistent in capitalisation, e.g. "3. Technical Uncertainty" + # vs "Technical uncertainty". Matching skip_sheets by exact equality would + # fail to skip these, so match case-insensitively by whether a skip name + # occurs anywhere in the (trimmed) sheet name instead. + is_skipped <- vapply(trimws(all_sheets), function(s) { + any(vapply(skip_sheets, function(skip) grepl(tolower(skip), tolower(s), fixed = TRUE), + logical(1))) + }, logical(1)) + data_sheets <- all_sheets[!is_skipped] results <- list() for (s in data_sheets) { message("Parsing ", basename(xlsx_path), ": ", s) res <- tryCatch({ - if (s == "Topical agents") { + if (trimws(s) == "Topical agents") { parse_topical_sheet(xlsx_path) + } else if (trimws(s) %in% c("5. Yeast", "6. Aspergillus")) { + parse_yeast_sheet(xlsx_path, s) } else { parse_sheet(xlsx_path, s) } @@ -674,11 +1087,11 @@ parse_workbook <- function(xlsx_path, } # ============================================================================== -# 8. Run +# 10. Run # ============================================================================== breakpoint_files <- list.files(path = "data-raw", - pattern = "breakpoint_table.*xlsx", + pattern = "breakpoint.*table.*[.]xlsx$", full.names = TRUE, recursive = FALSE, ignore.case = TRUE) @@ -714,12 +1127,392 @@ breakpoints_eucast_raw <- breakpoints_eucast saveRDS(breakpoints_eucast_raw, "data-raw/breakpoints_eucast_raw.rds") write.csv(breakpoints_eucast_raw, "data-raw/breakpoints_eucast_raw.csv", row.names = FALSE) + +# Cleanup for `clinical_breakpoints` table ---- +# This section derives the AMR::clinical_breakpoints-compatible +# `breakpoints_eucast` table from `breakpoints_eucast_raw`, following the +# same conventions as the WHONET-based `breakpoints_new` build (see +# data-raw/reproduction_of_clinical_breakpoints.R): guideline/type/host/ +# method/mo/ab/rank_index/ref_tbl/disk_dose/breakpoint_S/breakpoint_R/uti/ +# is_SDD, arranged and de-duplicated the same way. +# +# mo resolution needs pre-processing the WHONET pipeline doesn't, because +# EUCAST expresses organism scope as free text rather than as a single +# coded taxon per row (both at sheet level, e.g. "Bacillus spp. except +# B. anthracis", and at row level via split_agent_organism()'s +# mo_override, e.g. "other staphylococci" or "E. coli, Klebsiella spp. +# (except K. aerogenes), Raoultella spp. and P. mirabilis"): +# +# 1. An "except ..." / "other than ..." clause attached to a taxon does +# NOT need expanding into every other member of that taxon: the +# exception is already handled by rank_index precedence, since the +# named exception (e.g. B. anthracis, K. aerogenes) gets its own more +# specific row from its own sheet or its own list entry, which takes +# priority over the broader row at lookup time. This mirrors how the +# currently published clinical_breakpoints handles it (confirmed: +# "Bacillus" stays at genus rank alongside separate species-level +# "Bacillus anthracis" rows; same for Corynebacterium). The clause is +# therefore just stripped before mo resolution, wherever it occurs. +# 2. Elliptical phrasing that refers back to the sheet's own organism +# rather than naming a taxon ("other staphylococci", "other +# enterococci", "other Enterobacterales") is resolved to the sheet +# name itself, which already resolves correctly via as.mo(). +# 3. Cells naming two or more taxa jointly, e.g. "Aerococcus sanguinicola +# and A. urinae" or "E. coli, Klebsiella spp. (except K. aerogenes), +# Raoultella spp. and P. mirabilis", are split into one row per named +# taxon before resolution: as.mo() cannot reliably resolve a joint +# string (it either mismatches to a single subspecies or fails +# outright), whereas each individual member resolves correctly on its +# own, matching how the currently published dataset represents such +# cases (as separate rows, not a joint entry). +strip_mo_exceptions <- function(x) { + trimws(sub("\\s*\\(?(except|other than)\\b.*$", "", x, ignore.case = TRUE, perl = TRUE)) +} + +# Whole-cell variant of the above, used before any list-splitting is +# attempted. Only strips a trailing except/other-than clause when it is NOT +# wrapped in parentheses attached to a single list member -- e.g. +# "Bacillus spp. except B. anthracis" and "Corynebacterium spp. other than +# C. diphtheriae and C. ulcerans" both run genuinely to the end of the cell +# with no further list content, so the whole tail is dropped. By contrast, +# "E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +# P. mirabilis" has its exception parenthesized and attached to only one +# list member, with more members following afterward; stripping from +# "except" to the end of the whole string there would wrongly discard +# "Raoultella spp. and P. mirabilis" too. That case is intentionally left +# untouched here and handled per-member by strip_mo_exceptions() inside +# split_mo_list() instead, after the list has already been split apart. +strip_mo_exceptions_wholecell <- function(x) { + trimws(sub("\\s*(except|other than)\\b(?![^(]*\\)).*$", "", x, ignore.case = TRUE, perl = TRUE)) +} + +# Extracts a single trailing parenthetical qualifier from an antibiotic-name +# string, e.g. "Cefuroxime oral (uncomplicated UTI only)" -> "uncomplicated +# UTI only". Returns NA where no such qualifier is present. This is captured +# into `site` before the qualifier is stripped from `ab`, so that route- or +# indication-specific variants of the same drug (e.g. "... iv" vs "... oral +# (uncomplicated UTI only)") remain distinguishable by the distinct() step +# below, rather than colliding when their S breakpoint happens to match. +extract_trailing_parenthetical <- function(x) { + m <- regexpr("(?<=\\()[^)]*(?=\\)\\s*$)", x, perl = TRUE) + out <- rep(NA_character_, length(x)) + found <- m != -1 + out[found] <- regmatches(x, m) + out +} + +resolve_other_x <- function(x, sheet_name) { + # A few agent-name-embedded organism restrictions use elliptical phrasing + # that refers back to the sheet's own organism rather than naming a taxon + # directly, e.g. Staphylococcus sheet: "other staphylococci"; Enterococcus + # sheet: "other enterococci"; Enterobacterales sheet: "other + # Enterobacterales". In every observed case this means "the sheet's own + # genus/order", which the sheet name itself already resolves to directly + # (as.mo("Staphylococcus") -> genus Staphylococcus, etc.), so the fallback + # is simply the sheet name, not a species enumeration. + if_else(grepl("^other\\b", trimws(x), ignore.case = TRUE), sheet_name, x) +} + +expand_abbreviated_genus <- function(pieces, fallback_genus = NA_character_) { + # Tracks the most recently seen fully-spelled genus within a split list + # and expands any subsequent "X. species" abbreviation sharing its first + # letter to use it in full, e.g. in "Corynebacterium diphtheriae and + # C. ulcerans", the "C." in the second piece is expanded to + # "Corynebacterium" before as.mo() sees it. This matters because a bare + # genus initial is often genuinely ambiguous across many genera -- e.g. + # as.mo("C. ulcerans") alone resolves to Campylobacter upsaliensis, not + # Corynebacterium ulcerans, since there is no context to prefer one + # genus over another -- whereas the fully-qualified name is unambiguous. + # A piece is only expanded if its abbreviation letter actually matches + # the tracked genus's initial, so e.g. the leading "E. coli" in an + # Enterobacterales list is correctly left alone (nothing precedes it to + # expand from), and an abbreviation that happens to not match the most + # recent genus is also left alone rather than expanded incorrectly. + # + # fallback_genus seeds this tracking before the list is scanned, for + # sheets whose organism scope is itself a single genus (e.g. the + # Staphylococcus sheet's "S. pseudintermedius, S. intermedius, + # S. schleiferi and S. coagulans" never spells out "Staphylococcus" even + # once, so without a seed nothing would ever be expanded, and + # as.mo("S. intermedius") alone resolves to the wrong genus entirely -- + # Streptococcus intermedius, not Staphylococcus intermedius). Only pass + # a fallback_genus when the sheet's own organism is confirmed to resolve + # to genus rank (see split_mo_list()); an order-level sheet name like + # "Enterobacterales" must never be used this way, since it shares a + # first letter with genera it has nothing to do with (e.g. "E. coli"). + # + # A bare lowercase species epithet with no genus marker at all (e.g. + # "urinae" in "Aerococcus sanguinicola and urinae", an older EUCAST + # phrasing -- see split_mo_list_one()) is likewise expanded against the + # tracked genus, prefixed rather than substituted since there is no + # abbreviation to replace. + current_genus <- fallback_genus + vapply(pieces, function(p) { + full_match <- regmatches(p, regexpr("^[A-Z][a-z]+(?=\\s)", p, perl = TRUE)) + if (length(full_match) == 1 && nzchar(full_match)) { + current_genus <<- full_match + return(p) + } + if (!is.na(current_genus) && grepl("^[A-Z]\\.\\s", p) && + substr(p, 1, 1) == substr(current_genus, 1, 1)) { + return(sub("^[A-Z]\\.", current_genus, p)) + } + if (!is.na(current_genus) && grepl("^[a-z]+$", p)) { + return(paste(current_genus, p)) + } + p + }, character(1), USE.NAMES = FALSE) +} + +split_mo_list <- function(x, sheet_name = NA_character_) { + # Splits a free-text organism cell into one entry per named taxon. Handles: + # - a single taxon (returned unchanged) + # - two taxa joined by "and", e.g. "Aerococcus sanguinicola and A. urinae" + # - N taxa in a comma/"and" list, e.g. "E. coli, Klebsiella spp. (except + # K. aerogenes), Raoultella spp. and P. mirabilis" + # An "(except ...)" or "except ..." clause attached to one list member is + # stripped from that member only (not the whole cell), since it scopes to + # that member alone, e.g. "Klebsiella spp. (except K. aerogenes)" becomes + # "Klebsiella spp." -- the exclusion itself needs no further handling, by + # the same rank_index-precedence reasoning as the sheet-level case. + # Named species groups such as "Streptococcus groups A, B, C and G" or + # "Viridans group streptococci" must NOT be split; they are recognised by + # not matching the "Genus species" shape on at least one piece, and are + # returned unchanged so as.mo() resolves them directly to their + # species-group code. + + # Resolve each distinct sheet's own organism once (not per row -- x and + # sheet_name are typically thousands of rows spanning ~40 distinct + # sheets), to use as an abbreviation seed (see expand_abbreviated_genus()) + # only when the sheet's organism is itself a single genus. An order-level + # sheet (e.g. Enterobacterales) or a sheet whose name doesn't resolve at + # all correctly gets no fallback, since the sheet-genus seed would either + # be meaningless (an order is not a genus) or misleading (matching a + # first letter shared with an unrelated genus, e.g. "Enterobacterales" + # sharing "E" with "Escherichia" but not being that genus). + distinct_sheets <- unique(sheet_name[!is.na(sheet_name)]) + genus_lookup <- setNames(rep(NA_character_, length(distinct_sheets)), distinct_sheets) + for (sn in distinct_sheets) { + sheet_mo <- suppressWarnings(suppressMessages(as.mo(sn, info = FALSE))) + if (!is.na(sheet_mo) && isTRUE(mo_rank(sheet_mo) == "genus")) { + genus_lookup[sn] <- mo_genus(sheet_mo) + } + } + + map2(x, sheet_name, function(s, sn) { + sheet_genus_fallback <- if (!is.na(sn) && sn %in% names(genus_lookup)) genus_lookup[[sn]] else NA_character_ + split_mo_list_one(s, sheet_genus_fallback) + }) +} + +split_mo_list_one <- function(s, sheet_genus_fallback) { + s_clean <- trimws(gsub("[\r\n]+", " ", s)) + s_clean <- gsub("\u00A0", " ", s_clean, fixed = TRUE) # normalise non-breaking spaces (seen in some source cells) + # Normalise a missing space after a genus-abbreviation period, e.g. a + # v12.0 source typo "S.lugdunensis" -> "S. lugdunensis". Safe as a + # blanket fix: it only matches an uppercase letter immediately followed + # by "." and a lowercase letter with no space, which never occurs + # correctly formed any other way in these cells. + s_clean <- gsub("([A-Z])\\.(?=[a-z])", "\\1. ", s_clean, perl = TRUE) + # Split on commas and top-level " and " (not inside parentheses) + pieces <- unlist(strsplit(s_clean, ",(?![^(]*\\))|\\s+and\\s+(?![^(]*\\))", perl = TRUE)) + pieces <- trimws(pieces) + pieces <- pieces[pieces != ""] + pieces <- strip_mo_exceptions(pieces) + pieces <- trimws(gsub("\\s*\\(\\s*\\)\\s*$", "", pieces)) # drop now-empty "()" leftovers + + if (length(pieces) <= 1) return(s_clean) + + # Only treat as a genuine multi-taxon list if every piece looks like a + # taxon on its own: either an abbreviated genus initial ("E.", "P." + # followed by a species epithet), a capitalised word of 2+ letters + # (a full genus/organism name, "spp.", or the start of a longer + # descriptive name such as "Streptococcus groups A"), a bare lowercase + # species epithet with no genus marker at all, or the specific known + # descriptive phrase "coagulase-negative staphylococci" (e.g. + # "S. aureus and coagulase-negative staphylococci except S. epidermidis + # and S. lugdunensis" on the Staphylococcus sheet, after the trailing + # "except" clause is stripped by strip_mo_exceptions_wholecell() further + # up, splits into "S. aureus" and this phrase). Other free-text + # descriptive phrases are deliberately NOT accepted here even though + # as.mo() can often resolve them: at its default matching tolerance + # as.mo() will also resolve genuinely unrelated text to *something* + # rather than fail, so a broad allowance here would risk silently + # mapping real garbage to a wrong organism instead of correctly falling + # back to the unsplit string. The bare lowercase epithet case is a + # genuine, if unusual, EUCAST phrasing seen in older breakpoint tables + # (v9.0-v12.0): "Aerococcus sanguinicola and urinae" and "Campylobacter + # jejuni and coli" both drop the second species' genus abbreviation + # entirely (newer versions write "and A. urinae" / "and C. coli"). Left + # unhandled, the whole cell would either fail to resolve (Aerococcus + # case) or silently resolve to the wrong thing -- as.mo("Campylobacter + # jejuni and coli") matches a subspecies, not the two intended species + # -- so it is accepted here and expanded against the preceding piece's + # genus in expand_abbreviated_genus(), the same way an "X." abbreviation + # is. A bare single uppercase letter with no following text or period -- + # e.g. the "B", "C", "G" that a naive comma/"and" split produces from + # "Streptococcus groups A, B, C and G" -- still fails every one of these + # shapes, correctly signalling that the comma/"and" split misfired on a + # named group description rather than a genuine taxon list, so the + # whole cell falls back to the original, unsplit string. + looks_like_taxon <- grepl("^[A-Z]\\.\\s", pieces) | grepl("^[A-Z][a-z]+(\\.|\\s|$)", pieces) | + grepl("^[a-z]+$", pieces) | grepl("^coagulase-negative staphylococci$", pieces, ignore.case = TRUE) + if (!all(looks_like_taxon)) return(s_clean) + + # Reject a piece containing more than one capitalised, 3+ letter word + # (a rough genus/proper-name detector): this signals two taxa were + # fused into one piece because a separating comma was missing in the + # source cell, e.g. a v12.0 typo "Citrobacter spp. Klebsiella spp." + # (every other version correctly has a comma there). as.mo() does not + # reliably fail on such a fused string -- it can silently match an + # unrelated species with a similar combined shape (observed: + # as.mo("Citrobacter spp. Klebsiella spp.") resolves to Citrobacter + # enshiensis) -- so this must be caught before as.mo() ever sees it, + # by falling back to the unsplit original string. + genus_like_count <- vapply(pieces, function(p) length(gregexpr("\\b[A-Z][a-z]{2,}\\b", p, perl = TRUE)[[1]]), + integer(1)) + if (any(genus_like_count > 1)) return(s_clean) + + expand_abbreviated_genus(pieces, fallback_genus = sheet_genus_fallback) +} + breakpoints_eucast <- breakpoints_eucast_raw |> filter(!breakpoint_S %in% c("NOTE", "IE", "IP", "NA", "-"), !breakpoint_R %in% c("NOTE", "IE", "IP", "NA", "-")) |> - mutate(breakpoint_S = as.numeric(breakpoint_S), - breakpoint_R = as.numeric(breakpoint_R), - uti = uti | ab %like_case% "UTI") |> - filter(!(is.na(breakpoint_S) & is.na(breakpoint_R))) + mutate( + mo_text = strip_mo_exceptions_wholecell(mo), + mo_text = resolve_other_x(mo_text, sheet), + mo_text = split_mo_list(mo_text, sheet_name = sheet) + ) |> + tidyr::unnest(mo_text) |> + mutate( + # ref_tbl is pure metadata for a human reviewer to trace a row back to + # its exact source: the sheet name plus which file/version it came + # from, e.g. "6. Aspergillus (file: Antifungal Clinical Breakpoint + # Table v. 12.1)". file_desc is the version string's own description + # of the table (see detect_version()), so this stays correct + # automatically as new EUCAST versions are added, without needing any + # per-file naming convention here. + ref_tbl = if_else(!is.na(file_desc), paste0(trimws(sheet), " (file: ", file_desc, ")"), sheet), + mo = as.mo(mo_text) + ) |> + select(-file_desc) -breakpoints_eucast %>% count(guideline, version) +# AMR's internal diagnostic caches (AMR:::AMR_env$mo_uncertainties, +# AMR:::AMR_env$ab_previously_coerced) are reset by the *next* top-level +# as.mo()/as.ab() call, not preserved across a pipeline -- by the time the +# whole mutate() chain below finishes (four further mo_rank() calls, then +# as.ab()), only whatever the very last such call happened to leave behind +# would still be there, which is not a reliable record of every uncertain +# match made while building this table. Capture both immediately after the +# call that produced them, into script-owned variables, so they survive +# for inspection regardless of what AMR functions run afterward or how the +# script is subsequently sourced. +mo_uncertainties_eucast <- AMR:::AMR_env$mo_uncertainties +if (nrow(mo_uncertainties_eucast) > 0) { + message("NOTE: ", nrow(mo_uncertainties_eucast), " organism string(s) were resolved with uncertainty ", + "(matched below the default confidence, or against multiple candidates). ", + "Inspect `mo_uncertainties_eucast` and cross-check against the source sheet before trusting these rows.") +} + +breakpoints_eucast <- breakpoints_eucast |> + mutate( + rank_index = case_when( + is.na(mo_rank(mo, keep_synonyms = TRUE)) ~ 6, # for UNKNOWN, B_GRAMN, B_ANAER, etc. + mo_rank(mo, keep_synonyms = TRUE) %like% "(infra|sub)" ~ 1, + mo_rank(mo, keep_synonyms = TRUE) == "species" ~ 2, + mo_rank(mo, keep_synonyms = TRUE) == "species group" ~ 2.5, + mo_rank(mo, keep_synonyms = TRUE) == "genus" ~ 3, + mo_rank(mo, keep_synonyms = TRUE) == "family" ~ 4, + mo_rank(mo, keep_synonyms = TRUE) == "order" ~ 5, + TRUE ~ 6 + ), + # The route/indication qualifier (if any) is captured into `site` before + # it is stripped from `ab`, e.g. "Cefuroxime oral (uncomplicated UTI + # only)" -> ab = "Cefuroxime oral", site = "uncomplicated UTI only". + # This keeps the iv/oral or indication-specific variants of the same + # drug+organism+method distinguishable in the distinct() step below + # (site is part of its key); without it, e.g. "Cefuroxime iv" and + # "Cefuroxime oral (uncomplicated UTI only)" against the same organism + # would otherwise collide on identical (ab, mo, method, breakpoint_S) + # if their S breakpoints happen to match, silently losing one of them. + # uti is derived from that same qualifier text: every "UTI" mention in + # the raw agent-name text is confirmed to sit inside a trailing + # parenthetical qualifier, never in the base drug name itself, so no + # separate check against the (by this point already-coded) ab is needed. + qualifier = extract_trailing_parenthetical(ab), + site = coalesce(site, qualifier), + ab_input = gsub("\\s*\\(.*$", "", ab), # also fixes a source cell missing a space before "(", e.g. "Meropenem(indications..." + ab = as.ab(ab_input) + ) + +# ab_previously_coerced also logs every intermediate word-by-word fallback +# as.ab() tries internally while resolving a route-suffixed name (e.g. for +# "Ampicillin iv", it separately tries "IV", "AMPICILLIN", and "ORAL"-like +# fragments as candidate matches before landing on the correct whole-string +# result) -- these are internal matching noise, not genuine coercions of +# anything actually in this table, and would otherwise dominate the log. +# Restrict to rows whose logged input is one of the actual, full ab_input +# strings this pipeline passed in, which is what a reviewer needs to see. +ab_previously_coerced_eucast <- AMR:::AMR_env$ab_previously_coerced |> + filter(tolower(trimws(x_bak)) %in% tolower(trimws(unique(breakpoints_eucast$ab_input)))) +breakpoints_eucast <- breakpoints_eucast |> select(-ab_input) +if (nrow(ab_previously_coerced_eucast) > 0) { + message("NOTE: ", nrow(ab_previously_coerced_eucast), " antibiotic string(s) were resolved via approximate/previous-coercion ", + "matching rather than an exact code or name match. ", + "Inspect `ab_previously_coerced_eucast` and cross-check against the source sheet before trusting these rows.") +} + +breakpoints_eucast <- breakpoints_eucast |> + mutate( + breakpoint_S = as.numeric(breakpoint_S), + breakpoint_R = as.numeric(breakpoint_R), + uti = qualifier %like_case% "UTI", + is_SDD = FALSE # EUCAST has no "susceptible, dose dependent" category (CLSI-only concept) + ) |> + select(-mo_text, -qualifier) |> + # Greek symbols and EM dash symbols are not allowed by CRAN, so replace them with ASCII: + mutate(disk_dose = disk_dose %>% + gsub("\u03bc", "mc", ., fixed = TRUE) %>% # this is 'mu', \u03bc + gsub("\u00b5", "mc", ., fixed = TRUE) %>% # this is 'micro', \u00b5 (yes, they look the same) + gsub("\u2013", "-", ., fixed = TRUE) %>% + gsub("(?<=\\d)(?=[a-zA-Z])", " ", ., perl = TRUE)) # keep a space after a number, e.g. "1mcg" to "1 mcg" + +# Surface any rows whose organism or antibiotic text failed to resolve, +# rather than letting the final filter() drop them silently -- a growing +# list here across EUCAST versions usually means a new free-text pattern +# needs handling above, not a data error. +# +# as.mo() returns the literal code "UNKNOWN" rather than NA when it finds +# no match at all (unlike as.ab(), which returns NA), so a plain +# is.na(mo) check misses genuine resolution failures entirely. UNKNOWN is +# not automatically wrong to keep -- it is a real, meaningful category +# already used throughout this table (e.g. the rank_index case_when +# above), and the currently published clinical_breakpoints legitimately +# contains hundreds of such rows for cases EUCAST itself left organism- +# unspecific. It is reported here for review rather than dropped +# outright, since only a source-text defect that split_mo_list_one() +# doesn't yet handle (checked by cross-referencing ref_tbl/ab against the +# source sheet) would make a specific UNKNOWN row here spurious rather +# than a genuine EUCAST ambiguity. +unresolved_mo <- breakpoints_eucast |> filter(is.na(mo) | mo == "UNKNOWN") |> distinct(sheet, ref_tbl, ab) +unresolved_ab <- breakpoints_eucast |> filter(is.na(ab)) |> distinct(sheet, ab) +if (nrow(unresolved_mo) > 0) { + message("NOTE: ", nrow(unresolved_mo), " row(s) have an organism that either could not be resolved (NA, will be dropped) ", + "or resolved to UNKNOWN (kept, but review whether this is a genuine EUCAST ambiguity or a parsing gap):") + print(unresolved_mo) +} +if (nrow(unresolved_ab) > 0) { + message("NOTE: ", nrow(unresolved_ab), " distinct antibiotic string(s) could not be resolved by as.ab() and will be dropped:") + print(unresolved_ab) +} + +breakpoints_eucast <- breakpoints_eucast |> + filter(!(is.na(breakpoint_S) & is.na(breakpoint_R)), !is.na(mo), !is.na(ab)) |> + distinct(guideline, type, host, ab, mo, method, site, breakpoint_S, .keep_all = TRUE) |> + select(guideline, type, host, method, site, mo, rank_index, ab, ref_tbl, + disk_dose, breakpoint_S, breakpoint_R, uti, is_SDD, note) |> + arrange(desc(guideline), mo, ab, type, host, method) + +breakpoints_eucast %>% count(guideline) +glimpse(breakpoints_eucast) diff --git a/data-raw/_reproduction_scripts/reproduction_of_dosage.R b/data-raw/_reproduction_scripts/reproduction_of_dosage.R index 58e3accc9..eaaf1c0ba 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_dosage.R +++ b/data-raw/_reproduction_scripts/reproduction_of_dosage.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_reproduction_scripts/reproduction_of_example_isolates_unclean.R b/data-raw/_reproduction_scripts/reproduction_of_example_isolates_unclean.R index a612ff289..8b905affc 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_example_isolates_unclean.R +++ b/data-raw/_reproduction_scripts/reproduction_of_example_isolates_unclean.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_reproduction_scripts/reproduction_of_intrinsic_resistant.R b/data-raw/_reproduction_scripts/reproduction_of_intrinsic_resistant.R index 1feb551f9..6cd6af44f 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_intrinsic_resistant.R +++ b/data-raw/_reproduction_scripts/reproduction_of_intrinsic_resistant.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_reproduction_scripts/reproduction_of_microorganisms.R b/data-raw/_reproduction_scripts/reproduction_of_microorganisms.R index f7374c2aa..a3827f777 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_microorganisms.R +++ b/data-raw/_reproduction_scripts/reproduction_of_microorganisms.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/_reproduction_scripts/reproduction_of_microorganisms.groups.R b/data-raw/_reproduction_scripts/reproduction_of_microorganisms.groups.R index dc1f6bdca..a9cf9eddc 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_microorganisms.groups.R +++ b/data-raw/_reproduction_scripts/reproduction_of_microorganisms.groups.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/breakpoints_eucast_raw.csv b/data-raw/breakpoints_eucast_raw.csv index c898b142a..e87a88ac5 100644 --- a/data-raw/breakpoints_eucast_raw.csv +++ b/data-raw/breakpoints_eucast_raw.csv @@ -1,15011 +1,12592 @@ -"guideline","version","type","host","method","site","mo","rank_index","ab","ref_tbl","disk_dose","breakpoint_S","breakpoint_R","uti","is_SDD","is_screening","note","sheet" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [C] Susceptibility inferred from ampicillin.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [C] Susceptibility inferred from ampicillin.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","17",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] Breakpoints still under consideration.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] Breakpoints still under consideration.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam (uncomplicated UTI only) -E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone for E. coli.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam (uncomplicated UTI only) -E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone for E. coli.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales","10 mcg","22","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales",NA,"0.125","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen),Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin","Enterobacterales","30 mcg","18","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin","Enterobacterales","10 mcg","17","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales","10 mcg","15","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin","Enterobacterales","10 mcg","17","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] Tigecycline has poor activity against Morganella morganii, Proteus spp. and Providencia spp. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method.","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] Tigecycline has poor activity against Morganella morganii, Proteus spp. and Providencia spp. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method.","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only)","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales","5 mcg","18","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","18","18",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","18","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","24","24",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin","Pseudomonas spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin","Pseudomonas spp.","30 mcg","18","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin","Pseudomonas spp.","10 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.","10 mcg","12","12",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin","Pseudomonas spp.","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"4","4",FALSE,FALSE,FALSE,"[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below).","S.maltophilia" -"EUCAST 2019","9.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,"[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below).","S.maltophilia" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin","Acinetobacter spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin","Acinetobacter spp.","30 mcg","19","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [E] For screening for methicillin resistance in S. pseudintermedius, see Note C on cephalosporins.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [E] For screening for methicillin resistance in S. pseudintermedius, see Note C on cephalosporins.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For dosing, see table of dosages. -2.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[2] For dosing, see table of dosages. -2.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. epidermidis","Staphylococcus spp.","30 mcg","25","25",FALSE,FALSE,FALSE,"[3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. pseudintermedius","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] Cefoxitin screen for methicillin resistance in S. pseudintermedius is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm to screen for methicillin resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[6/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[6/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen)","Staphylococcus spp.","10 mcg","17","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","18","16",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin,Coagulase-negative staphylococci","Staphylococcus spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin,Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","18","18",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Examine zone edges with transmitted light (plate held up to light).","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,"[A] Examine zone edges with transmitted light (plate held up to light).","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [B] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [B] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","21","18",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.","15 mcg","18","18",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen)","Streptococcus groups A, B, C and G","10 mcg","12","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","4",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","16",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae","2 mcg","22","16",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. For oxacillin non-susceptible isolates, always determine the MIC of benzylpenicillin.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.03","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen)","Streptococcus pneumoniae","10 mcg","10","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","4",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","17",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen)","Viridans group streptococci","1 unit","18","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci","30 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Perform an MIC test.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Perform an MIC test.","Viridans group streptococci" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae","2 mcg","16","16",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/C] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae","10/10 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] For use in meningitis determine the meropenem MIC value.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] For use in meningitis determine the meropenem MIC value.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen)","Haemophilus influenzae","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.125","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen)","Moraxella catarrhalis","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","28","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin","Neisseria meningitidis",NA,"0.06","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem(meningitis)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline","Neisseria meningitidis",NA,"1","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline","Neisseria meningitidis",NA,"1","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Benzylpenicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin-sulbactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin-tazobactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Phenoxymethylpenicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Cefoxitin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ceftolozane-tazobactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ertapenem","Gram-positive anaerobes -except Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Imipenem","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem-vaborbactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Moxifloxacin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Dalbavancin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Oritavancin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Teicoplanin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Telavancin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Vancomycin","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Erythromycin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Clindamycin","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Doxycycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Eravacycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Minocycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tetracycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tigecycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Chloramphenicol","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Metronidazole","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" -"EUCAST 2019","9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"C.difficile" -"EUCAST 2019","9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin","Gram-negative anaerobes",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem","Gram-negative anaerobes",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem","Gram-negative anaerobes",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem","Gram-negative anaerobes",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol","Gram-negative anaerobes",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen)","Pasteurella multocida","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2019","9.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2019","9.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. -Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","17",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone. for E. coli","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone. for E. coli","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales","10 mcg","22","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganella spp.","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganella spp.","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only)","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","24","24",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2020","10.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi, see Note C on cephalosporins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi, see Note C on cephalosporins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.","30 mcg","25","25",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius and S. schleiferi","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] Cefoxitin screen for methicillin resistance in S. pseudintermediusand S. schleiferi is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm to screen for methicillin resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[7/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[7/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test. -C.Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test. -C.Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","Note",FALSE,FALSE,FALSE,"[C] ","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","20",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The zone diameter breakpoint is valid for MSSA only. For MRSA, perform an MIC test.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] The zone diameter breakpoint is valid for MSSA only. For MRSA, perform an MIC test.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","Note",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae","2 mcg","22","16",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","17",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","18","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci","30 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae","10/10 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","28","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin","Neisseria meningitidis",NA,"0.06","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Benzylpenicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin-sulbactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin-tazobactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Phenoxymethylpenicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Cefoxitin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ceftolozane-tazobactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ertapenem","Gram-positive anaerobes -except Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Imipenem","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Imipenem-relebactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem-vaborbactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Moxifloxacin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Dalbavancin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Oritavancin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Teicoplanin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Telavancin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Vancomycin","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Erythromycin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Clindamycin","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Doxycycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Eravacycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Minocycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tetracycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tigecycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Chloramphenicol","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Metronidazole","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" -"EUCAST 2020","10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"C.difficile" -"EUCAST 2020","10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin","Gram-negative anaerobes",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem","Gram-negative anaerobes",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem","Gram-negative anaerobes",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam","Gram-negative anaerobes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem","Gram-negative anaerobes",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol","Gram-negative anaerobes",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","Pasteurella multocida","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" -"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" -"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","50","23",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" -"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2020","10.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2020","10.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","25","25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","20","20",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. -ND = No ECOFF available.","Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. -ND = No ECOFF available.","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","30","30",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[C] Breakpoints still under consideration. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[C] Breakpoints still under consideration. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)","Pseudomonas spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2021","11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2021","11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2021","11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). -4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), -S. pseudintermedius and S. schleiferi","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.","30 mcg","25","25",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), -S. pseudintermedius and S. schleiferi","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), -S. pseudintermedius and S. schleiferi","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline(indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline(indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","Note",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","Note",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","16",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[E] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC for meropenem.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC for meropenem.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","17",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","18","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam,S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam,S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae","10/10 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","28","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Benzylpenicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin-sulbactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin-tazobactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Phenoxymethylpenicillin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Cefiderocol","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Cefoxitin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ceftolozane-tazobactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Doripenem","Gram-positive anaerobes -except Clostridioides difficile",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ertapenem","Gram-positive anaerobes -except Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Imipenem","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Imipenem-relebactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem-vaborbactam","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Moxifloxacin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Dalbavancin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Oritavancin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Teicoplanin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Telavancin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Vancomycin","Gram-positive anaerobes -except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Erythromycin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Clindamycin","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Doxycycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Eravacycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Minocycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tetracycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tigecycline","Gram-positive anaerobes -except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Chloramphenicol","Gram-positive anaerobes -except Clostridioides difficile",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Lefamulin","Gram-positive anaerobes -except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Metronidazole","Gram-positive anaerobes -except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" -"EUCAST 2021","11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"C.difficile" -"EUCAST 2021","11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin","Gram-negative anaerobes",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doripenem","Gram-negative anaerobes",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem","Gram-negative anaerobes",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem","Gram-negative anaerobes",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam","Gram-negative anaerobes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem","Gram-negative anaerobes",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol","Gram-negative anaerobes",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","Pasteurella multocida","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2021","11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2021","11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2021","11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2021","11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2021","11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2021","11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. -except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" -"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" -"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","50","23",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" -"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2021","11.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2021","11.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2021","11.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","20","20",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. -ND = No ECOFF available.","Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. -ND = No ECOFF available.","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp. Klebsiella spp.,  -Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp. Klebsiella spp.,  -Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2022","12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2022","12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2022","12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudinter-medius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S.lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S.lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), -S. pseudintermedius, S. schleiferi and -S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), -S. pseudintermedius, S. schleiferi and -S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","18","18",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (prophylaxis only)","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, -B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, -B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","Pasteurella multocida","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","P.multocida" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" -"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida" -"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2022","12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2022","12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2022","12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2022","12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2022","12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2022","12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","18","18",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. -except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2022","12.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2022","12.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2022","12.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. -ND = No ECOFF available.","Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. -ND = No ECOFF available.","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and -P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents.The ECOFF is 256 mg/L.","Pseudomonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2023","13.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2023","13.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2023","13.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), -S. pseudintermedius, S. schleiferi and -S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), -S. pseudintermedius, S. schleiferi and -S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, -B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, -B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2023","13.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2023","13.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. -except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2023","13.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2023","13.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2023","13.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. -ND = No ECOFF available.","Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. -ND = No ECOFF available.","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents.The ECOFF is 256 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2023","13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2023","13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2023","13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), -S. pseudintermedius, S. schleiferi and -S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), -S. pseudintermedius, S. schleiferi and -S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, -B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, -B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2023","13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2023","13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. -except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2023","13.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2023","13.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2023","13.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. -ND = No ECOFF available.","Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. -ND = No ECOFF available.","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2024","14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2024","14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2024","14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","17",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[1/A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors. | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors. | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2024","14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2024","14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. -except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis","1 unit","50","18",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis",NA,"0.001","0.25",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis","5 mcg","10","10",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis","30 mcg","26","26",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis","5 mcg","12","12",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis","30 mcg","30","30",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis","5 mcg","50","27",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis","5 mcg","50","28",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis","10 mcg","23","23",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis","10 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis","30 mcg","42","42",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " -"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis","5 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " -"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " -"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " -"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2024","14.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2024","14.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2024","14.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. -ND = No ECOFF available.","Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. -ND = No ECOFF available.","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales","30/20 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","27","27",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales","30/20 mcg","25","25",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), -E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), -E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim -(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","S.maltophilia" -"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","S.maltophilia" -"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.maltophilia" -"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.maltophilia" -"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant.","Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant.","Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","17",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.","2 mcg","10","10",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,TRUE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G","1 unit","23","23",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","1",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","1 unit","Note","Note",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.25","1",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci",NA,"21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci",NA,"1","1",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci",NA,"12","12",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci","2 mcg","21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","32","32",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility can be inferred from the nalidixic acid screening test. | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae","2/1 mcg","22","22",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","A.xylosoxidans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","A.xylosoxidans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. -except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis","1 unit","50","18",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis",NA,"0.001","0.25",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis","5 mcg","10","10",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis","30 mcg","26","26",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis","5 mcg","12","12",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis","30 mcg","30","30",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis","5 mcg","50","27",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis","5 mcg","50","28",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis","10 mcg","23","23",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis","10 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis","30 mcg","42","42",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " -"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis","5 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " -"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " -"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " -"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2025","15.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2025","15.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2025","15.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. -ND = No ECOFF available.","Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. -ND = No ECOFF available.","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales","30/20 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime -(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","27","27",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales","30/20 mcg","25","25",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral -(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gepotidacin (uncomplicated UTI only),E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gepotidacin (uncomplicated UTI only),E. coli","Enterobacterales",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), -E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), Proteus spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[7/G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), Proteus spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[7/G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, -Enterobacterales except Serratia spp.","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, -Enterobacterales except Serratia spp.","Enterobacterales","1.25/23.75 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, -Serratia spp.","Enterobacterales",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, -Serratia spp.","Enterobacterales","1.25/23.75 mcg","50","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than -P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than -P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, -P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","S.maltophilia" -"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","S.maltophilia" -"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1/A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia" -"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1/A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia" -"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,NA,"Acinetobacter" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except -S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except -S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","17",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, -Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, -Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, -Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, -Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), -S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","19","19",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.","2 mcg","10","10",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,TRUE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. -Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. -Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),E. faecalis","Enterococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),E. faecalis","Enterococcus spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), -E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), -E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G","1 unit","23","23",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin -Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. -2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), -S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","1",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","1 unit","Note","Note",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefadroxil","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefadroxil","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefalexin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefalexin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefazolin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefazolin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","15","15",FALSE,FALSE,FALSE,NA,"S.pneumoniae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.25","1",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci",NA,"1","1",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci","1 unit","12","12",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci","2 mcg","21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). -Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. -Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Daptomycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Daptomycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[5/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","32","32",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"H.influenzae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","15","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" -NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,"[6/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[6/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,"[3/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[3/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin","Fusobacterium necrophorum and Fusobacterium nucleatum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin","Fusobacterium necrophorum and Fusobacterium nucleatum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum and Fusobacterium nucleatum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum","30/6 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem","Fusobacterium necrophorum and Fusobacterium nucleatum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem","Fusobacterium necrophorum and Fusobacterium nucleatum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem","Fusobacterium necrophorum and Fusobacterium nucleatum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin","Fusobacterium necrophorum and Fusobacterium nucleatum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole","Fusobacterium necrophorum and Fusobacterium nucleatum","5 mcg","30","30",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin","Clostridium innocuum",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin","Clostridium innocuum","2 mcg","21","21",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam","Clostridium innocuum",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam","Clostridium innocuum","10/10 mcg","28","28",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin","Clostridium innocuum",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin","Clostridium innocuum",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid","Clostridium innocuum",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid","Clostridium innocuum","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam","Clostridium innocuum",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam","Clostridium innocuum","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Meropenem","Clostridium innocuum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Meropenem","Clostridium innocuum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Clindamycin","Clostridium innocuum",NA,"2","2",FALSE,FALSE,TRUE,"[4/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Clindamycin","Clostridium innocuum","2 mcg","17","17",FALSE,FALSE,TRUE,"[4/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Metronidazole","Clostridium innocuum",NA,"4","4",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Metronidazole","Clostridium innocuum","5 mcg","19","19",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Benzylpenicillin","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Benzylpenicillin","Clostridium ramosum","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin","Clostridium ramosum","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam","Clostridium ramosum","10/10 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin","Clostridium ramosum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid","Clostridium ramosum","2/1 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam","Clostridium ramosum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam","Clostridium ramosum","30/6 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ertapenem","Clostridium ramosum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ertapenem","Clostridium ramosum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Imipenem","Clostridium ramosum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Imipenem","Clostridium ramosum","10 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Meropenem","Clostridium ramosum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Meropenem","Clostridium ramosum","10 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Metronidazole","Clostridium ramosum",NA,"4","4",FALSE,FALSE,FALSE,"[5/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Metronidazole","Clostridium ramosum","5 mcg","21","21",FALSE,FALSE,FALSE,"[5/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Benzylpenicillin","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Benzylpenicillin","Clostridium septicum","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin","Clostridium septicum","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam","Clostridium septicum","10/10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin","Clostridium septicum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid","Clostridium septicum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid","Clostridium septicum","2/1 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam","Clostridium septicum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam","Clostridium septicum","30/6 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ertapenem","Clostridium septicum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ertapenem","Clostridium septicum","10 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Imipenem","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Imipenem","Clostridium septicum","10 mcg","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Meropenem","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Meropenem","Clostridium septicum","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Vancomycin","Clostridium septicum",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Vancomycin","Clostridium septicum","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Clindamycin","Clostridium septicum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Clindamycin","Clostridium septicum","2 mcg","24","24",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Metronidazole","Clostridium septicum",NA,"4","4",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Metronidazole","Clostridium septicum","5 mcg","21","21",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin","Clostridium tertium","2 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam","Clostridium tertium","10/10 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin","Clostridium tertium",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin","Clostridium tertium",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid","Clostridium tertium",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid","Clostridium tertium","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ertapenem","Clostridium tertium",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ertapenem","Clostridium tertium",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Imipenem","Clostridium tertium",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Imipenem","Clostridium tertium","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Meropenem","Clostridium tertium",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Meropenem","Clostridium tertium","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Vancomycin","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Vancomycin","Clostridium tertium","5 mcg","13","13",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Metronidazole","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,"[3/B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Metronidazole","Clostridium tertium","5 mcg","20","20",FALSE,FALSE,FALSE,"[3/B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33A","33",FALSE,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Benzylpenicillin","Cutibacterium avidum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Benzylpenicillin","Cutibacterium avidum","1 unit","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin","Cutibacterium avidum","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam","Cutibacterium avidum","10/10 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin","Cutibacterium avidum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid","Cutibacterium avidum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam","Cutibacterium avidum",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam","Cutibacterium avidum","30/6 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Cefotaxime","Cutibacterium avidum",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Cefotaxime","Cutibacterium avidum","5 mcg","24","24",FALSE,FALSE,FALSE,"[5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ceftriaxone","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ceftriaxone","Cutibacterium avidum","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ertapenem","Cutibacterium avidum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ertapenem","Cutibacterium avidum","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Imipenem","Cutibacterium avidum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Imipenem","Cutibacterium avidum","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Meropenem","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Meropenem","Cutibacterium avidum","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Vancomycin","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Vancomycin","Cutibacterium avidum","5 mcg","19","19",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Clindamycin","Cutibacterium avidum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Clindamycin","Cutibacterium avidum","2 mcg","33","33",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Linezolid","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Linezolid","Cutibacterium avidum","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Benzylpenicillin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Benzylpenicillin","Finegoldia spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin","Finegoldia spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam","Finegoldia spp.","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin","Finegoldia spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid","Finegoldia spp.","2/1 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam","Finegoldia spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam","Finegoldia spp.","30/6 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ertapenem","Finegoldia spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ertapenem","Finegoldia spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Imipenem","Finegoldia spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Imipenem","Finegoldia spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Meropenem","Finegoldia spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Meropenem","Finegoldia spp.","10 mcg","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Vancomycin","Finegoldia spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Vancomycin","Finegoldia spp.","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Clindamycin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Clindamycin","Finegoldia spp.","2 mcg","23","23",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Metronidazole","Finegoldia spp.",NA,"2","2",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Metronidazole","Finegoldia spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Benzylpenicillin","Parvimonas micra",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Benzylpenicillin","Parvimonas micra","1 unit","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin","Parvimonas micra",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin","Parvimonas micra","2 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam","Parvimonas micra","10/10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin","Parvimonas micra",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid","Parvimonas micra","2/1 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam","Parvimonas micra","30/6 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ertapenem","Parvimonas micra",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ertapenem","Parvimonas micra","10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Imipenem","Parvimonas micra",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Imipenem","Parvimonas micra","10 mcg","40","40",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Meropenem","Parvimonas micra",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Meropenem","Parvimonas micra","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Vancomycin","Parvimonas micra",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Vancomycin","Parvimonas micra","5 mcg","19","19",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Clindamycin","Parvimonas micra",NA,"1","1",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Clindamycin","Parvimonas micra","2 mcg","18","18",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Metronidazole","Parvimonas micra",NA,"1","1",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Metronidazole","Parvimonas micra","5 mcg","28","28",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin","Peptostreptococcus anaerobius",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin","Peptostreptococcus anaerobius","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin","Peptostreptococcus anaerobius","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam","Peptostreptococcus anaerobius","10/10 mcg","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin","Peptostreptococcus anaerobius",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid","Peptostreptococcus anaerobius","2/1 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam","Peptostreptococcus anaerobius","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem","Peptostreptococcus anaerobius",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem","Peptostreptococcus anaerobius","10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Imipenem","Peptostreptococcus anaerobius",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Imipenem","Peptostreptococcus anaerobius","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Meropenem","Peptostreptococcus anaerobius",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Meropenem","Peptostreptococcus anaerobius","10 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin","Peptostreptococcus anaerobius",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin","Peptostreptococcus anaerobius","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,TRUE,"[6/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin","Peptostreptococcus anaerobius","2 mcg","17","17",FALSE,FALSE,TRUE,"[6/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole","Peptostreptococcus anaerobius",NA,"2","2",FALSE,FALSE,FALSE,"[7/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole","Peptostreptococcus anaerobius","5 mcg","22","22",FALSE,FALSE,FALSE,"[7/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin","Peptoniphilus spp.","1 unit","18","18",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin","Peptoniphilus spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam","Peptoniphilus spp.","10/10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid","Peptoniphilus spp.","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam","Peptoniphilus spp.","30/6 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ertapenem","Peptoniphilus spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ertapenem","Peptoniphilus spp.","10 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Imipenem","Peptoniphilus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Imipenem","Peptoniphilus spp.","10 mcg","37","37",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Meropenem","Peptoniphilus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Meropenem","Peptoniphilus spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Vancomycin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Vancomycin","Peptoniphilus spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Clindamycin","Peptoniphilus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Clindamycin","Peptoniphilus spp.","2 mcg","15","15",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Metronidazole","Peptoniphilus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Metronidazole","Peptoniphilus spp.","5 mcg","19","19",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" -NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" -"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella" -"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","18","18",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae","2/1 mcg","22","22",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" -"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","A.xylosoxidans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","A.xylosoxidans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" -"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","Bacillus spp. -except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","Bacillus spp. -except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","Bacillus spp. -except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. -except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","Bacillus spp. -except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","Bacillus spp. -except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","Bacillus spp. -except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","Bacillus spp. -except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis","1 unit","50","18",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis",NA,"0.001","0.25",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis","5 mcg","10","10",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis","30 mcg","26","26",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"B.anthracis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis","5 mcg","12","12",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis","30 mcg","30","30",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis","5 mcg","50","27",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis","5 mcg","50","28",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis","10 mcg","23","23",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis","10 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis","30 mcg","42","42",FALSE,FALSE,FALSE,NA,"B.melitensis " -"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " -"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis","5 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " -"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " -"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " -"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" -"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" -"EUCAST 2026","16.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2026","16.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2026","16.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis" -"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" -"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" +"guideline","version","file_desc","type","host","method","site","mo","rank_index","ab","disk_dose","breakpoint_S","breakpoint_R","note","sheet" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[C] Susceptibility inferred from ampicillin.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","16",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[5] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[5] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Mecillinam (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Mecillinam (uncomplicated UTI only)","10 mcg","15","15","[D] Ignore isolated colonies within the inhibition zone for E. coli.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","5 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen)","30 mcg","19","19","[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"1","1","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","30 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","19","19",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","10 mcg","22","17",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem",NA,"0.125","4","[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem","10 mcg","50","17","[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem",NA,"2","8",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","10 mcg","22","16",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen)","5 mcg","24","24","[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","1",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin",NA,"8","16",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin","30 mcg","18","15",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin","10 mcg","17","14",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","10 mcg","15","12",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin","10 mcg","17","14",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","IP mcg","IP","IP",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","18","15",NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"16","16",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"16","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"16","16",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"16","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"8","8",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","21","21",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"8","8",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","17","17",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","24","24",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"4","4",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","20","20",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","10 mcg","24","18",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"16","16",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"1","1",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin",NA,"8","16",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin","30 mcg","18","15",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin",NA,"4","4",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin","10 mcg","15","15",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"4","4",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","10 mcg","12","12",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin",NA,"4","4",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin","10 mcg","16","16",NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"4","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem",NA,"2","8",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","10 mcg","21","15",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.06","1",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin",NA,"8","16",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin","30 mcg","19","17",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","10 mcg","16","16",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"4","8",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","21","18",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen)","10 mcg","12","12","[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","IP mcg","IP","IP",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","18","18","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","19","19",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin",NA,"0.25","0.25","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","1 unit","18","18","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","17","17","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen)","10 mcg","12","Note","[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","4","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","16","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"Note","Note","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin",NA,"0.5","2","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","2 mcg","22","16","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen)","1 mcg","20","Note","[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.03","0.5",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25","[3] Meropenem is the only carbapenem used for meningitis.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC. | [3] Meropenem is the only carbapenem used for meningitis.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","16","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen)","10 mcg","10","Note","[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","21","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","4",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","19",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.06","0.5",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen)","1 unit","18","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","30 mcg","IP","IP",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","IP mcg","IP","IP",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.25","0.25",NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid",NA,"Note","Note","[A] Perform an MIC test.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","2 mcg","16","16","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [C] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.125","1",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25","[3] Meropenem is the only carbapenem used for meningitis.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note","[C] For use in meningitis determine the meropenem MIC value. | [3] Meropenem is the only carbapenem used for meningitis.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","21","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.125","4",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"2","2","[1] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","30 mcg","30","30","[A] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin",NA,"0.06","1","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.06","0.25",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem(meningitis)",NA,"0.25","0.25","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03","[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"1","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol",NA,"2","2",NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25","[1] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin",NA,"0.125","0.125","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","1 unit","13","13",NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin","2 mcg","16","16",NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen)","30 mcg","23","Note","[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen)","30 mcg","24","24","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","26","26",NA,"C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"1","1",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","10 mcg","23","23",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note","[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpointss apply only to tests performed on Middlebrook 7H11/7H10 medium. Comparability of tests performed by other media has not been established.","M.tuberculosis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","16",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[5] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[C] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (uncomplicated UTI only)","10 mcg","15","15","[D] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","IP mcg","IP","IP",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","5 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[4] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","30 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","10 mcg","22","17",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem","10 mcg","50","17","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales except Morganella spp.",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales except Morganella spp.",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem",NA,"2","8",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","10 mcg","22","16",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24","[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","24","24","[2] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","10 mcg","24","18",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","1",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","22",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem",NA,"2","8",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","10 mcg","21","15",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin",NA,"0.25","0.25","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","1 unit","18","18","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","Note","[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin",NA,"0.5","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","2 mcg","22","16","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note","[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","Note","[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.5",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","30 mcg","IP","IP",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.25","0.25",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","IP mcg","IP","IP","[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"2","2","[1] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","30 mcg","30","30","[A] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.06","0.25",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)",NA,"0.25","0.25","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03","[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] See table of dosages.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25","[2] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","1 unit","13","13",NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","2 mcg","16","16",NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","26","26",NA,"C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note","[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","50","23","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","25","25",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","20","20",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","30","30",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[5] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24","[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)","10 mcg","24","24",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","1",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","22",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","S.maltophilia" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. pseudintermedius and S. schleiferi",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci other than S. epidermidis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci other than S. epidermidis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. epidermidis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. epidermidis",NA,"Cefoxitin (screen only)","30 mcg","25","25","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. pseudintermedius and S. schleiferi",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. pseudintermedius and S. schleiferi",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline(indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline(indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin",NA,"Note","Note","[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","Note","[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","22","22","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","22","22","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","19","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","2",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","18",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","19","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","21","21","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"8","8",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","30 mcg","18","18",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32","[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Use an MIC method.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","5 mcg","26","23",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","Note","[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","16","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note","[E] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC for meropenem.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","Note","[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8","[1] For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21","[1] For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.5",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125","[4] The breakpoints also apply to meningitis.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125","[4] The breakpoints also apply to meningitis.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1","[1] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)",NA,"0.25","0.25","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03","[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25","[2] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin",NA,"8","16","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Cefiderocol",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Doripenem",NA,"1","1",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Lefamulin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doripenem",NA,"1","1",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","2 mcg","16","16",NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note","[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","50","23","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"IE","IE","[2] MIC data have been generated with MGIT system and not with the EUCAST reference method. Therefore, it has not been possible to set an ECOFF, nor calibrate MGIT MIC values against the reference method. Consequently, EUCAST cannot endorse the tentative breakpoint set by EMA based on the MGIT method. Breakpoints are pending MIC data with the reference method.","M.tuberculosis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","20","20",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Citrobacter spp. Klebsiella spp.,  Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[5] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Citrobacter spp. Klebsiella spp.,  Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24","[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. pseudinter-medius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. epidermidis and S.lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. epidermidis and S.lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","2",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","18",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","2",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","18",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","2",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","19",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","30 mcg","18","18","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Use an MIC method.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing. +.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing. +.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note","[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","18","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (prophylaxis only)",NA,"0.03","0.03",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"B. thetaiotaomicron",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"B. thetaiotaomicron",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1","[2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28","[A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","20","20","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","18","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"IE","IE","[2] MIC data have been generated with MGIT system and not with the EUCAST reference method. Therefore, it has not been possible to set an ECOFF, nor calibrate MGIT MIC values against the reference method. Consequently, EUCAST cannot endorse the tentative breakpoint set by EMA based on the MGIT method. Breakpoints are pending MIC data with the reference method.","M.tuberculosis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Amphotericin B",NA,"0.001","2","[1] The entire C. auris wild-type population is in the I category. The Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any WT strains as ""S"" strains.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Amphotericin B",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Anidulafungin",NA,"0.016","0.016",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Anidulafungin",NA,"0.25","0.25",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Anidulafungin",NA,"0.03","0.03",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Anidulafungin",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Anidulafungin",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Anidulafungin",NA,"4","4",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Anidulafungin",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Anidulafungin",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Caspofungin",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Caspofungin",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Caspofungin",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Fluconazole",NA,"Note","Note","[3] The fluconazole susceptibility of the earliest C. auris strains (likely representing the wild-type, e.g.CBS10913) was low (4 mg/L, determined in-house by EUCAST), and C. auris isolates with low azole MICs are still reported, particularly from South America. However, most C. auris isolates exhibit fluconazole MIC values >16 mg/L and harbour acquired resistance mechanisms. Due to the paucity of true wild-type, non-outbreak isolates, a fluconazole ECOFF cannot be established. Clinical data on isolates with lower MICs (≤ 16 mg/L) are very limited. Therefore, EUCAST has insufficient data to support fluconazole therapy for C. auris, even when the MIC is low.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Fluconazole",NA,"0.001","16","[4] The entire C. glabrata wild-type population is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any wild-typestrains as ""S"" strains.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Fluconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Fluconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Itraconazole",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Itraconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Itraconazole",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Itraconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Itraconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Itraconazole",NA,"0.125","0.125",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Itraconazole",NA,"0.125","0.125",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Itraconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Itraconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Micafungin",NA,"0.03","0.03",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Micafungin",NA,"0.25","0.25",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Micafungin",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Micafungin",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Micafungin",NA,"IE","IE","[6] MICs for C. krusei are approximately three two-fold dilution steps higher than those for C. albicans and, similarly, those for C. guilliermondii are approximately eight two-fold dilutions higher. In addition, there were only a small number of cases involving these species in the clinical trials. This means there is insufficient evidence (IE) to indicate whether the wild-type population of these pathogens can be considered susceptible to micafungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Micafungin",NA,"4","4",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Micafungin",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Micafungin",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Posaconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Posaconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Posaconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Posaconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Posaconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Rezafungin",NA,"0.008","0.008","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Rezafungin",NA,"IE","IE","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Rezafungin",NA,"0.016","0.016","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Rezafungin",NA,"0.016","0.016","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Rezafungin",NA,"0.03","0.03","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Rezafungin",NA,"4","4","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Rezafungin",NA,"0.03","0.03","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Rezafungin",NA,"IE","IE","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Voriconazole",NA,"0.06","0.25","[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Voriconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Voriconazole",NA,"0.06","0.25","[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Voriconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Voriconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Voriconazole",NA,"0.125","0.25",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Voriconazole",NA,"0.125","0.25","[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Voriconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Voriconazole",NA,"IE","IE",NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Amphotericin B",NA,"1","1",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Amphotericin B",NA,"1","1",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Isavuconazole",NA,"1","1",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Isavuconazole",NA,"1","1",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Isavuconazole",NA,"0.5","0.5",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Isavuconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Isavuconazole",NA,"1","1",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Itraconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus. | [4] The MIC values for isolates of A. niger and A. versicolor are in general higher than those for A. fumigatus. Whether this translates into a poorer clinical response is unknown.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Posaconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Posaconazole",NA,"0.125","0.125",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Posaconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Posaconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Posaconazole",NA,"0.125","0.125",NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Voriconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Voriconazole",NA,"1","1","[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Voriconazole",NA,"1","1","[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Voriconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Voriconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [4] Breakpoints for fosfomycin iv are currently under review.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21","[D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below). | [4] Breakpoints for fosfomycin iv are currently under review.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). The ECOFF is 256 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). | [3] Breakpoints for fosfomycin iv are currently under review.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Use an MIC method. | [3] Breakpoints for fosfomycin iv are currently under review.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","20",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2","[3] Breakpoints for trimethoprim are currently under review.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP","[3] Breakpoints for trimethoprim are currently under review.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","23",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","21","12",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","5 mcg","Note","Note","[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","23",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25","[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14","[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[2] A provisional screen value of ≤2 mg/L can be used for antimicrobial susceptibility testing with Mycobacteria Growth Indicator Tube (MGIT, Becton Dickinson). There are insufficient MIC data with the reference method to set a clinical breakpoint.","M.tuberculosis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note","[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum",NA,"4","4","[1] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum","5 mcg","12","12","[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","21","12",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","12","12","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","30","30","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"0.5","0.5","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination. | [2] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. +ND = No ECOFF available.","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. +ND = No ECOFF available.","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","30/20 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[7] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","27","24",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","27","27",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam",NA,"4","4","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","30/20 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[4] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE","[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. +4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. +4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.25","0.25","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv",NA,"4","4",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","2 mcg","10","10","[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"0.001","4","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin",NA,"0.001","16",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin","30 mcg","50","18",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin-tazobactam",NA,"0.001","16","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin-tazobactam","30/6 mcg","50","18","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note","[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis and E. faecium",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis and E. faecium",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other enterococci",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other enterococci",NA,"Vancomycin","5 mcg","15","15",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.25","0.25",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin","1 unit","23","23",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin","1 unit","18","18",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)",NA,"0.06","1",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","1 unit","Note","Note","[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)","2 mcg","22","19",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)",NA,"0.25","1",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","1 unit","21","12",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"0.25","0.25",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"21","21",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"1","1","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"12","12","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","2 mcg","21","15",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","2 mcg","21","21",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE","[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[3] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","32","32","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","12","12","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","30","30","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"0.5","0.5","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination. | [2] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","23","23",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","30/20 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[7] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","27","24",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","27","27",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam",NA,"4","4","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","30/20 mcg","25","25",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Gepotidacin (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Proteus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[7] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Proteus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Serratia spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Serratia spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Serratia spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Serratia spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","15","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[4] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE","[1] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE","[A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE","[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. +4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. +4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.25","0.25","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Daptomycin",NA,"Note","Note","[3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[4] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Gepotidacin (uncomplicated UTI only)",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","19","19",NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","24","24","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv",NA,"4","4",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","2 mcg","10","10","[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"0.001","4","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin",NA,"0.001","16",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin","30 mcg","50","18",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin-tazobactam",NA,"0.001","16","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin-tazobactam","30/6 mcg","50","18","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note","[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis and E. faecium",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis and E. faecium",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other enterococci",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other enterococci",NA,"Vancomycin","5 mcg","15","15",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.25","0.25",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Gepotidacin (uncomplicated UTI only)",NA,"8","8",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin","1 unit","23","23",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin","1 unit","18","18",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)",NA,"0.06","1",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","1 unit","Note","Note","[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)","2 mcg","22","19",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefadroxil",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefadroxil",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefalexin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefalexin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefazolin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefazolin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)",NA,"0.25","1",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","1 unit","21","12",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"0.25","0.25",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","1 unit","21","21",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"1","1","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","1 unit","12","12","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","2 mcg","21","15",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","2 mcg","21","21",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE","[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Daptomycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Daptomycin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)",NA,"Note","Note","[3] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)",NA,"Note","Note","[C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [5] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[3] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[3] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.03","0.03",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","32","32","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4","[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25","[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4","[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. nucleatum",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. nucleatum",NA,"Amoxicillin-clavulanic acid",NA,"23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. necrophorum",NA,"Piperacillin-tazobactam",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. nucleatum",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. nucleatum",NA,"Piperacillin-tazobactam",NA,"35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole",NA,"1","1","[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole","5 mcg","30","30","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin",NA,"1","1",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin","2 mcg","21","21",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam","10/10 mcg","28","28",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Meropenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Meropenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Clindamycin",NA,"2","2","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Clindamycin","2 mcg","17","17","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Metronidazole","5 mcg","19","19","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Benzylpenicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Benzylpenicillin","1 unit","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin","2 mcg","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam","10/10 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam","30/6 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Imipenem","10 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Meropenem",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Meropenem","10 mcg","22","22","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Metronidazole","5 mcg","21","21","[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Benzylpenicillin","1 unit","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam","10/10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam","30/6 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ertapenem","10 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Imipenem","10 mcg","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Meropenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Vancomycin",NA,"4","4",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Vancomycin","5 mcg","14","14",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Clindamycin",NA,"0.5","0.5",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Clindamycin","2 mcg","24","24","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Metronidazole","5 mcg","21","21","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin",NA,"4","4",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin","2 mcg","12","12",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam","10/10 mcg","22","22",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Imipenem","10 mcg","28","28",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Meropenem","10 mcg","24","24",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Vancomycin",NA,"4","4",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Vancomycin","5 mcg","13","13",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Metronidazole",NA,"4","4","[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Metronidazole","5 mcg","20","20","[B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33A","33",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Cefotaxime",NA,"Note","Note","[3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Benzylpenicillin","1 unit","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam","10/10 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam",NA,"4","4","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam","30/6 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Cefotaxime",NA,"Note","Note","[5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Cefotaxime","5 mcg","24","24","[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ceftriaxone",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ceftriaxone","30 mcg","30","30","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Meropenem",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Meropenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Vancomycin","5 mcg","19","19",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Clindamycin",NA,"0.125","0.125",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Clindamycin","2 mcg","33","33","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Linezolid","10 mcg","28","28",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin","2 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam","30/6 mcg","30","30","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Imipenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Imipenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Meropenem","10 mcg","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Vancomycin",NA,"1","1",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Vancomycin","5 mcg","20","20",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Clindamycin",NA,"0.5","0.5","[5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Clindamycin","2 mcg","23","23","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Metronidazole",NA,"2","2","[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Metronidazole","5 mcg","25","25","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Benzylpenicillin",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Benzylpenicillin","1 unit","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin","2 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam","10/10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid","2/1 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam","30/6 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ertapenem","10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Imipenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Imipenem","10 mcg","40","40","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Meropenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Meropenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Vancomycin","5 mcg","19","19",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Clindamycin",NA,"1","1","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Clindamycin","2 mcg","18","18","[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Metronidazole",NA,"1","1","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Metronidazole","5 mcg","28","28","[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam","10/10 mcg","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem","10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Meropenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Meropenem","10 mcg","30","30","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin","5 mcg","15","15",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin",NA,"1","1","[6] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin","2 mcg","17","17","[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole",NA,"2","2","[7] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole","5 mcg","22","22","[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin","1 unit","18","18","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin","2 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam","10/10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam","30/6 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ertapenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ertapenem","10 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Imipenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Imipenem","10 mcg","37","37","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Meropenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Vancomycin",NA,"0.5","0.5",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Vancomycin","5 mcg","21","21",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Clindamycin",NA,"2","2","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Clindamycin","2 mcg","15","15","[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Metronidazole","5 mcg","19","19","[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","18","18","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","12","12","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","30","30","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"0.5","0.5","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] For bedaquiline, breakpoints were determined using the EUCAST reference method.","M.tuberculosis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06","[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. +3.The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods.","M.tuberculosis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. +3.The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods. | [4] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","23","23",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" diff --git a/data-raw/breakpoints_eucast_raw.rds b/data-raw/breakpoints_eucast_raw.rds index fcad05d9c..4beed643e 100644 Binary files a/data-raw/breakpoints_eucast_raw.rds and b/data-raw/breakpoints_eucast_raw.rds differ diff --git a/data-raw/eucast_new_from_xl.rds b/data-raw/eucast_new_from_xl.rds new file mode 100644 index 000000000..3ce546183 Binary files /dev/null and b/data-raw/eucast_new_from_xl.rds differ diff --git a/data-raw/loinc.R b/data-raw/loinc.R index 4dc5cc8b5..15c2b81d8 100644 --- a/data-raw/loinc.R +++ b/data-raw/loinc.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/poorman_prepend.R b/data-raw/poorman_prepend.R index 072e5f06c..4ea1531a7 100644 --- a/data-raw/poorman_prepend.R +++ b/data-raw/poorman_prepend.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/read_EUCAST.R b/data-raw/read_EUCAST.R index c2933bbcd..3980cda31 100644 --- a/data-raw/read_EUCAST.R +++ b/data-raw/read_EUCAST.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/salmonellae.R b/data-raw/salmonellae.R index fe890b1ca..e24f3827d 100644 --- a/data-raw/salmonellae.R +++ b/data-raw/salmonellae.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/data-raw/v_12.1_Antifungal_Breakpoint_Tables.xlsx b/data-raw/v_12.1_Antifungal_Breakpoint_Tables.xlsx new file mode 100644 index 000000000..57ce81551 Binary files /dev/null and b/data-raw/v_12.1_Antifungal_Breakpoint_Tables.xlsx differ diff --git a/data-raw/v_13.0_Breakpoint_Tables.xlsx b/data-raw/v_13.0_Breakpoint_Tables.xlsx deleted file mode 100644 index a917686f6..000000000 Binary files a/data-raw/v_13.0_Breakpoint_Tables.xlsx and /dev/null differ diff --git a/data-raw/v_16.0__BreakpointTables.xlsx b/data-raw/v_16.0__BreakpointTables.xlsx deleted file mode 100644 index 7d0ceefc7..000000000 Binary files a/data-raw/v_16.0__BreakpointTables.xlsx and /dev/null differ diff --git a/pkgdown/extra.css b/pkgdown/extra.css index 5373d4c4a..d995e63fa 100644 --- a/pkgdown/extra.css +++ b/pkgdown/extra.css @@ -13,7 +13,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/pkgdown/extra.js b/pkgdown/extra.js index 5774d8bcd..0c24aea37 100644 --- a/pkgdown/extra.js +++ b/pkgdown/extra.js @@ -13,7 +13,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat.R b/tests/testthat.R index b1039f04e..270fb2edf 100644 --- a/tests/testthat.R +++ b/tests/testthat.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/helper-functions.R b/tests/testthat/helper-functions.R index 721b99819..cec25b395 100644 --- a/tests/testthat/helper-functions.R +++ b/tests/testthat/helper-functions.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-_deprecated.R b/tests/testthat/test-_deprecated.R index 0d1037a41..7257ea380 100644 --- a/tests/testthat/test-_deprecated.R +++ b/tests/testthat/test-_deprecated.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-_misc.R b/tests/testthat/test-_misc.R index da6e9d3db..67533e4fb 100755 --- a/tests/testthat/test-_misc.R +++ b/tests/testthat/test-_misc.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-ab.R b/tests/testthat/test-ab.R index 46a630eb7..31de31f67 100755 --- a/tests/testthat/test-ab.R +++ b/tests/testthat/test-ab.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-ab_from_text.R b/tests/testthat/test-ab_from_text.R index 37d5c77b7..4a8daec63 100644 --- a/tests/testthat/test-ab_from_text.R +++ b/tests/testthat/test-ab_from_text.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-ab_property.R b/tests/testthat/test-ab_property.R index a0505a34d..5f3bcf666 100644 --- a/tests/testthat/test-ab_property.R +++ b/tests/testthat/test-ab_property.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-age.R b/tests/testthat/test-age.R index 530c950e5..4c2e32911 100644 --- a/tests/testthat/test-age.R +++ b/tests/testthat/test-age.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-amr_selectors.R b/tests/testthat/test-amr_selectors.R index 6f3ff771b..5e4e6e67c 100644 --- a/tests/testthat/test-amr_selectors.R +++ b/tests/testthat/test-amr_selectors.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-antibiogram.R b/tests/testthat/test-antibiogram.R index 6dab925a4..6f36ce2db 100644 --- a/tests/testthat/test-antibiogram.R +++ b/tests/testthat/test-antibiogram.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-atc_online.R b/tests/testthat/test-atc_online.R index 7f5680c85..8d4d3da27 100644 --- a/tests/testthat/test-atc_online.R +++ b/tests/testthat/test-atc_online.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-av.R b/tests/testthat/test-av.R index f0151d9a1..57a7730bd 100755 --- a/tests/testthat/test-av.R +++ b/tests/testthat/test-av.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-av_from_text.R b/tests/testthat/test-av_from_text.R index a8dd28472..0942b7bef 100644 --- a/tests/testthat/test-av_from_text.R +++ b/tests/testthat/test-av_from_text.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-av_property.R b/tests/testthat/test-av_property.R index a389ad053..f3dcae97a 100644 --- a/tests/testthat/test-av_property.R +++ b/tests/testthat/test-av_property.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-availability.R b/tests/testthat/test-availability.R index 36cad8f5a..0d8e4c9e4 100644 --- a/tests/testthat/test-availability.R +++ b/tests/testthat/test-availability.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-bug_drug_combinations.R b/tests/testthat/test-bug_drug_combinations.R index f60e00623..1c6dc9e19 100644 --- a/tests/testthat/test-bug_drug_combinations.R +++ b/tests/testthat/test-bug_drug_combinations.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-count.R b/tests/testthat/test-count.R index c298fba65..a39483386 100644 --- a/tests/testthat/test-count.R +++ b/tests/testthat/test-count.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-custom_antimicrobials.R b/tests/testthat/test-custom_antimicrobials.R index 9de11489f..618e9a1ad 100644 --- a/tests/testthat/test-custom_antimicrobials.R +++ b/tests/testthat/test-custom_antimicrobials.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-custom_microorganisms.R b/tests/testthat/test-custom_microorganisms.R index 491c91fa3..2a27a1e58 100644 --- a/tests/testthat/test-custom_microorganisms.R +++ b/tests/testthat/test-custom_microorganisms.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-data.R b/tests/testthat/test-data.R index babe42e81..5417d829f 100644 --- a/tests/testthat/test-data.R +++ b/tests/testthat/test-data.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-disk.R b/tests/testthat/test-disk.R index b67c6a6ba..340900685 100755 --- a/tests/testthat/test-disk.R +++ b/tests/testthat/test-disk.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-first_isolate.R b/tests/testthat/test-first_isolate.R index e47fe2320..efcea11a0 100755 --- a/tests/testthat/test-first_isolate.R +++ b/tests/testthat/test-first_isolate.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-g.test.R b/tests/testthat/test-g.test.R index 2b8c22a4d..f1343011b 100644 --- a/tests/testthat/test-g.test.R +++ b/tests/testthat/test-g.test.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-get_episode.R b/tests/testthat/test-get_episode.R index 32a1088e3..11c907eae 100644 --- a/tests/testthat/test-get_episode.R +++ b/tests/testthat/test-get_episode.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-ggplot_sir.R b/tests/testthat/test-ggplot_sir.R index 3eed98bbd..8b53d1279 100644 --- a/tests/testthat/test-ggplot_sir.R +++ b/tests/testthat/test-ggplot_sir.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-guess_ab_col.R b/tests/testthat/test-guess_ab_col.R index 5ef8e3954..f4d0a3a60 100644 --- a/tests/testthat/test-guess_ab_col.R +++ b/tests/testthat/test-guess_ab_col.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-interpretive_rules.R b/tests/testthat/test-interpretive_rules.R index f29fda12d..4ffa19b62 100755 --- a/tests/testthat/test-interpretive_rules.R +++ b/tests/testthat/test-interpretive_rules.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-italicise_taxonomy.R b/tests/testthat/test-italicise_taxonomy.R index 17862407d..965043f45 100644 --- a/tests/testthat/test-italicise_taxonomy.R +++ b/tests/testthat/test-italicise_taxonomy.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-join_microorganisms.R b/tests/testthat/test-join_microorganisms.R index 106d70eca..f83caa02a 100755 --- a/tests/testthat/test-join_microorganisms.R +++ b/tests/testthat/test-join_microorganisms.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-key_antimicrobials.R b/tests/testthat/test-key_antimicrobials.R index 6907c261a..8435b2c70 100644 --- a/tests/testthat/test-key_antimicrobials.R +++ b/tests/testthat/test-key_antimicrobials.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-kurtosis.R b/tests/testthat/test-kurtosis.R index cd89e6262..9fc163587 100644 --- a/tests/testthat/test-kurtosis.R +++ b/tests/testthat/test-kurtosis.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-like.R b/tests/testthat/test-like.R index c4b957ace..6e110be94 100644 --- a/tests/testthat/test-like.R +++ b/tests/testthat/test-like.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-mdro.R b/tests/testthat/test-mdro.R index 9d98f3a7d..721812921 100755 --- a/tests/testthat/test-mdro.R +++ b/tests/testthat/test-mdro.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-mean_amr_distance.R b/tests/testthat/test-mean_amr_distance.R index e69846d60..1cf203327 100644 --- a/tests/testthat/test-mean_amr_distance.R +++ b/tests/testthat/test-mean_amr_distance.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-mic.R b/tests/testthat/test-mic.R index fb8f48aa4..39c3f2a53 100755 --- a/tests/testthat/test-mic.R +++ b/tests/testthat/test-mic.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-mo.R b/tests/testthat/test-mo.R index 106fc433b..48472d21f 100644 --- a/tests/testthat/test-mo.R +++ b/tests/testthat/test-mo.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-mo_property.R b/tests/testthat/test-mo_property.R index 11774d9d1..b404630d7 100644 --- a/tests/testthat/test-mo_property.R +++ b/tests/testthat/test-mo_property.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-pca.R b/tests/testthat/test-pca.R index 99c7637b7..0ca055de2 100644 --- a/tests/testthat/test-pca.R +++ b/tests/testthat/test-pca.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-plotting.R b/tests/testthat/test-plotting.R index fc4a04143..da85f741e 100644 --- a/tests/testthat/test-plotting.R +++ b/tests/testthat/test-plotting.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-proportion.R b/tests/testthat/test-proportion.R index 58e489b9f..c7bdeaa2a 100755 --- a/tests/testthat/test-proportion.R +++ b/tests/testthat/test-proportion.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-random.R b/tests/testthat/test-random.R index 5f403bf50..77df92d9a 100644 --- a/tests/testthat/test-random.R +++ b/tests/testthat/test-random.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-sir.R b/tests/testthat/test-sir.R index a648a0e83..27128ab67 100644 --- a/tests/testthat/test-sir.R +++ b/tests/testthat/test-sir.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-skewness.R b/tests/testthat/test-skewness.R index e06508dd1..91f41bbe4 100644 --- a/tests/testthat/test-skewness.R +++ b/tests/testthat/test-skewness.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-tidymodels.R b/tests/testthat/test-tidymodels.R index 0f5df58c1..f9d4838eb 100755 --- a/tests/testthat/test-tidymodels.R +++ b/tests/testthat/test-tidymodels.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-top_n_microorganisms.R b/tests/testthat/test-top_n_microorganisms.R index ce1326a32..44a91f1dd 100644 --- a/tests/testthat/test-top_n_microorganisms.R +++ b/tests/testthat/test-top_n_microorganisms.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-translate.R b/tests/testthat/test-translate.R index a22ad14ac..276f417eb 100644 --- a/tests/testthat/test-translate.R +++ b/tests/testthat/test-translate.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-vctrs.R b/tests/testthat/test-vctrs.R index 480c631a7..f4ba5cf3a 100755 --- a/tests/testthat/test-vctrs.R +++ b/tests/testthat/test-vctrs.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/testthat/test-zzz.R b/tests/testthat/test-zzz.R index c2429c02c..a710e642d 100644 --- a/tests/testthat/test-zzz.R +++ b/tests/testthat/test-zzz.R @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute # diff --git a/tests/tinytest.R.old b/tests/tinytest.R.old index 8b5a57952..1ac7d1682 100644 --- a/tests/tinytest.R.old +++ b/tests/tinytest.R.old @@ -12,7 +12,7 @@ # https://doi.org/10.18637/jss.v104.i03 # # # # Developed at the University of Groningen and the University Medical # -# Center Groningen in The Netherlands, in collaboration with many # +# Center Groningen in the Netherlands, in collaboration with many # # colleagues from around the world, see our website. # # # # This R package is free software; you can freely use and distribute #